1
|
Kespohl M, Goetzke CC, Althof N, Bredow C, Kelm N, Pinkert S, Bukur T, Bukur V, Grunz K, Kaur D, Heuser A, Mülleder M, Sauter M, Klingel K, Weiler H, Berndt N, Gaida MM, Ruf W, Beling A. TF-FVIIa PAR2-β-Arrestin in Mouse Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection. Arterioscler Thromb Vasc Biol 2024. [PMID: 38385286 DOI: 10.1161/atvbaha.123.320157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 02/05/2024] [Indexed: 02/23/2024]
Abstract
BACKGROUND Accumulating evidence implicates the activation of G-protein-coupled PARs (protease-activated receptors) by coagulation proteases in the regulation of innate immune responses. METHODS Using mouse models with genetic alterations of the PAR2 signaling platform, we have explored contributions of PAR2 signaling to infection with coxsackievirus B3, a single-stranded RNA virus provoking multiorgan tissue damage, including the heart. RESULTS We show that PAR2 activation sustains correlates of severe morbidity-hemodynamic compromise, aggravated hypothermia, and hypoglycemia-despite intact control of the virus. Following acute viral liver injury, canonical PAR2 signaling impairs the restoration process associated with exaggerated type I IFN (interferon) signatures in response to viral RNA recognition. Metabolic profiling in combination with proteomics of liver tissue shows PAR2-dependent reprogramming of liver metabolism, increased lipid droplet storage, and gluconeogenesis. PAR2-sustained hypodynamic compromise, reprograming of liver metabolism, as well as imbalanced IFN responses are prevented in β-arrestin coupling-deficient PAR2 C-terminal phosphorylation mutant mice. Thus, wiring between upstream proteases and immune-metabolic responses results from biased PAR2 signaling mediated by intracellular recruitment of β-arrestin. Importantly, blockade of the TF (tissue factor)-FVIIa (coagulation factor VIIa) complex capable of PAR2 proteolysis with the NAPc2 (nematode anticoagulant protein c2) mitigated virus-triggered pathology, recapitulating effects seen in protease cleavage-resistant PAR2 mice. CONCLUSIONS These data provide insights into a TF-FVIIa signaling axis through PAR2-β-arrestin coupling that is a regulator of inflammation-triggered tissue repair and hemodynamic compromise in coxsackievirus B3 infection and can potentially be targeted with selective coagulation inhibitors.
Collapse
Affiliation(s)
- Meike Kespohl
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.K., C.B., N.K., S.P., A.B.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Berlin, Germany (M.K., A.B., K.G., D.K., W.R.)
| | - Carl Christoph Goetzke
- Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (C.C.G.)
- Clinician Scientist Program, BIH Academy, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Germany (C.C.G.)
- German Rheumatism Research Center, Leibniz Association, Berlin, Germany (C.C.G.)
| | - Nadine Althof
- German Federal Institute for Risk Assessment, Berlin, Germany (N.A.)
| | - Clara Bredow
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.K., C.B., N.K., S.P., A.B.)
| | - Nicolas Kelm
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.K., C.B., N.K., S.P., A.B.)
| | - Sandra Pinkert
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.K., C.B., N.K., S.P., A.B.)
| | - Thomas Bukur
- Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON), Germany (T.B., V.B.)
| | - Valesca Bukur
- Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON), Germany (T.B., V.B.)
| | - Kristin Grunz
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Berlin, Germany (M.K., A.B., K.G., D.K., W.R.)
- University Medical Center Mainz, Center for Thrombosis and Hemostasis, Germany (K.G., D.K., W.R.)
| | - Dilraj Kaur
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Berlin, Germany (M.K., A.B., K.G., D.K., W.R.)
- University Medical Center Mainz, Center for Thrombosis and Hemostasis, Germany (K.G., D.K., W.R.)
| | - Arnd Heuser
- Max-Delbrueck-Center for Molecular Medicine, Animal Phenotyping Platform, Berlin, Germany (A.H.)
| | - Michael Mülleder
- Core Facility High-Throughput Mass Spectrometry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.M.)
| | - Martina Sauter
- University Hospital Tuebingen, Institute for Pathology and Neuropathology, Cardiopathology, Germany (M.S., K.K.)
| | - Karin Klingel
- University Hospital Tuebingen, Institute for Pathology and Neuropathology, Cardiopathology, Germany (M.S., K.K.)
| | | | - Nikolaus Berndt
- Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (N.B.)
- German Institute of Human Nutrition Potsdam-Rehbruecke, Department of Molecular Toxicology, Nuthetal, Germany (N.B.)
- Deutsches Herzzentrum der Charité, Institute of Computer-Assisted Cardiovascular Medicine, Berlin, Germany (N.B.)
| | - Matthias M Gaida
- University Medical Center Mainz, Institute for Pathology, Johannes-Gutenberg-Universität Mainz, Germany (M.M.G.)
- University Medical Center Mainz, Research Center for Immunotherapy, Johannes-Gutenberg-Universität Mainz, Germany (M.M.G.)
- Joint Unit Immunopathology, Institute of Pathology, University Medical Center, Johannes Gutenberg University of Mainz, Germany (M.M.G.)
- TRON, Mainz, Germany (M.M.G.)
| | - Wolfram Ruf
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Berlin, Germany (M.K., A.B., K.G., D.K., W.R.)
- University Medical Center Mainz, Center for Thrombosis and Hemostasis, Germany (K.G., D.K., W.R.)
| | - Antje Beling
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany. (M.K., C.B., N.K., S.P., A.B.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner site Berlin, Germany (M.K., A.B., K.G., D.K., W.R.)
| |
Collapse
|
2
|
Kühnisch J, Theisen S, Dartsch J, Fritsche-Guenther R, Kirchner M, Obermayer B, Bauer A, Kahlert AK, Rothe M, Beule D, Heuser A, Mertins P, Kirwan JA, Berndt N, MacRae CA, Hubner N, Klaassen S. Prdm16 mutation determines sex-specific cardiac metabolism and identifies two novel cardiac metabolic regulators. Cardiovasc Res 2024; 119:2902-2916. [PMID: 37842925 PMCID: PMC10874277 DOI: 10.1093/cvr/cvad154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 07/04/2023] [Accepted: 07/18/2023] [Indexed: 10/17/2023] Open
Abstract
AIMS Mutation of the PRDM16 gene causes human dilated and non-compaction cardiomyopathy. The PRDM16 protein is a transcriptional regulator that affects cardiac development via Tbx5 and Hand1, thus regulating myocardial structure. The biallelic inactivation of Prdm16 induces severe cardiac dysfunction with post-natal lethality and hypertrophy in mice. The early pathological events that occur upon Prdm16 inactivation have not been explored. METHODS AND RESULTS This study performed in-depth pathophysiological and molecular analyses of male and female Prdm16csp1/wt mice that carry systemic, monoallelic Prdm16 gene inactivation. We systematically assessed early molecular changes through transcriptomics, proteomics, and metabolomics. Kinetic modelling of cardiac metabolism was performed in silico with CARDIOKIN. Prdm16csp1/wt mice are viable up to 8 months, develop hypoplastic hearts, and diminished systolic performance that is more pronounced in female mice. Prdm16csp1/wt cardiac tissue of both sexes showed reductions in metabolites associated with amino acid as well as glycerol metabolism, glycolysis, and the tricarboxylic acid cycle. Prdm16csp1/wt cardiac tissue revealed diminished glutathione (GSH) and increased inosine monophosphate (IMP) levels indicating oxidative stress and a dysregulated energetics, respectively. An accumulation of triacylglycerides exclusively in male Prdm16csp1/wt hearts suggests a sex-specific metabolic adaptation. Metabolic modelling using CARDIOKIN identified a reduction in fatty acid utilization in males as well as lower glucose utilization in female Prdm16csp1/wt cardiac tissue. On the level of transcripts and protein expression, Prdm16csp1/wt hearts demonstrate an up-regulation of pyridine nucleotide-disulphide oxidoreductase domain 2 (Pyroxd2) and the transcriptional regulator pre-B-cell leukaemia transcription factor interacting protein 1 (Pbxip1). The strongest concordant transcriptional up-regulation was detected for Prdm16 itself, probably through an autoregulatory mechanism. CONCLUSIONS Monoallelic, global Prdm16 mutation diminishes cardiac performance in Prdm16csp1/wt mice. Metabolic alterations and transcriptional dysregulation in Prdm16csp1/wt affect cardiac tissue. Female Prdm16csp1/wt mice develop a more pronounced phenotype, indicating sexual dimorphism at this early pathological window. This study suggests that metabolic dysregulation is an early event in the PRDM16 associated cardiac pathology.
Collapse
Affiliation(s)
- Jirko Kühnisch
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Simon Theisen
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Josephine Dartsch
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Raphaela Fritsche-Guenther
- BIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Marieluise Kirchner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Proteomics Platform, Berlin, Germany
- Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Benedikt Obermayer
- Core Unit Bioinformatics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Anna Bauer
- BIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Anne-Karin Kahlert
- Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital of Schleswig-Holstein, Kiel, Germany
- DZHK German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lübeck, Germany
- Institute of Immunology and Genetics, Kaiserslautern, Germany
| | | | - Dieter Beule
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- Core Unit Bioinformatics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Arnd Heuser
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Philipp Mertins
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Proteomics Platform, Berlin, Germany
- Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Jennifer A Kirwan
- BIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Nikolaus Berndt
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Institute of Computer-assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
- Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam—Rehbruecke (DIfE), Nuthetal, Germany
| | - Calum A MacRae
- Harvard Medical School and Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, USA
| | - Norbert Hubner
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Sabine Klaassen
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Department of Pediatric Cardiology, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
| |
Collapse
|
3
|
Bredow C, Thery F, Wirth EK, Ochs S, Kespohl M, Kleinau G, Kelm N, Gimber N, Schmoranzer J, Voss M, Klingel K, Spranger J, Renko K, Ralser M, Mülleder M, Heuser A, Knobeloch KP, Scheerer P, Kirwan J, Brüning U, Berndt N, Impens F, Beling A. ISG15 blocks cardiac glycolysis and ensures sufficient mitochondrial energy production during Coxsackievirus B3 infection. Cardiovasc Res 2024:cvae026. [PMID: 38309955 DOI: 10.1093/cvr/cvae026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 11/10/2023] [Accepted: 12/12/2023] [Indexed: 02/05/2024] Open
Abstract
AIMS Virus infection triggers inflammation and, may impose nutrient shortage to the heart. Supported by type I interferon (IFN) signaling, cardiomyocytes counteract infection by various effector processes, with the IFN-stimulated gene of 15 kDa (ISG15) system being intensively regulated and protein modification with ISG15 protecting mice Coxsackievirus B3 (CVB3) infection. The underlying molecular aspects how the ISG15 system affects the functional properties of respective protein substrates in the heart are unknown. METHODS AND RESULTS Based on the protective properties due to protein ISGylation, we set out a study investigating CVB3-infected mice in depth and found cardiac atrophy with lower cardiac output in ISG15-/- mice. By mass spectrometry, we identified the protein targets of the ISG15 conjugation machinery in heart tissue and explored how ISGylation affects their function. The cardiac ISGylome showed a strong enrichment of ISGylation substrates within glycolytic metabolic processes. Two control enzymes of the glycolytic pathway, hexokinase 2 (HK2) and phosphofructokinase muscle form (PFK1), were identified as bona fide ISGylation targets during infection. In an integrative approach complemented with enzymatic functional testing and structural modeling, we demonstrate that protein ISGylation obstructs the activity of HK2 and PFK1. Seahorse-based investigation of glycolysis in cardiomyocytes revealed that, by conjugating proteins, the ISG15 system prevents the infection-/IFN-induced upregulation of glycolysis. We complemented our analysis with proteomics-based advanced computational modeling of cardiac energy metabolism. Our calculations revealed an ISG15-dependent preservation of the metabolic capacity in cardiac tissue during CVB3 infection. Functional profiling of mitochondrial respiration in cardiomyocytes and mouse heart tissue by Seahorse technology showed an enhanced oxidative activity in cells with a competent ISG15 system. CONCLUSIONS Our study demonstrates that ISG15 controls critical nodes in cardiac metabolism. ISG15 reduces the glucose demand, supports higher ATP production capacity in the heart, despite nutrient shortage in infection, and counteracts cardiac atrophy and dysfunction.
Collapse
Affiliation(s)
- Clara Bredow
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
| | - Fabien Thery
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- VIB-UGent Center for Medical Biotechnology, Ghent, Belgium
| | - Eva Katrin Wirth
- Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany
| | - Sarah Ochs
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
| | - Meike Kespohl
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany
| | - Gunnar Kleinau
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charitéplatz 1, Berlin, Germany
| | - Nicolas Kelm
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
| | - Niclas Gimber
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany
| | - Jan Schmoranzer
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Advanced Medical Bioimaging Core Facility, Berlin, Germany
| | - Martin Voss
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
| | - Karin Klingel
- University of Tübingen, Cardiopathology, Institute for Pathology and Neuropathology, Tübingen, Germany
| | - Joachim Spranger
- Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology, Diabetes and Nutrition, Berlin, Germany
| | - Kostja Renko
- German Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), Berlin, Germany
| | - Markus Ralser
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility - High-Throughput Mass Spectrometry, Berlin, Germany
| | - Michael Mülleder
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Core Facility - High-Throughput Mass Spectrometry, Berlin, Germany
| | - Arnd Heuser
- Animal Phenotyping Platform, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - Klaus-Peter Knobeloch
- University of Freiburg, Institute of Neuropathology, Freiburg, Germany
- CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany
| | - Patrick Scheerer
- Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Physics and Biophysics, Group Protein X-ray Crystallography and Signal Transduction, Charitéplatz 1, Berlin, Germany
| | - Jennifer Kirwan
- Berlin Institute of Health (BIH) @ Charité, Metabolomics Platform, Berlin, Germany
- Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Ulrike Brüning
- Berlin Institute of Health (BIH) @ Charité, Metabolomics Platform, Berlin, Germany
- Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Nikolaus Berndt
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute for Computational and Imaging Science in Cardiovascular Medicine, Berlin, Germany
| | - Francis Impens
- Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
- VIB-UGent Center for Medical Biotechnology, Ghent, Belgium
- VIB Proteomics Core, Ghent, Belgium
| | - Antje Beling
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biochemistry, Berlin, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung, partner site Berlin, Berlin, Germany
| |
Collapse
|
4
|
Sholokh A, Walter S, Markó L, McMurray BJ, Sunaga-Franze DY, Xu M, Zühlke K, Russwurm M, Bartolomaeus TUP, Langanki R, Qadri F, Heuser A, Patzak A, Forslund SK, Bähring S, Borodina T, Persson PB, Maass PG, Bader M, Klussmann E. Mutant phosphodiesterase 3A protects the kidney from hypertension-induced damage. Kidney Int 2023:S0085-2538(23)00389-7. [PMID: 37244472 DOI: 10.1016/j.kint.2023.04.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/20/2023] [Accepted: 04/27/2023] [Indexed: 05/29/2023]
Affiliation(s)
- Anastasiia Sholokh
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany
| | - Stephan Walter
- MVZ Nierenzentrum Limburg, Im Großen Rohr 14, 65549 Limburg, Germany
| | - Lajos Markó
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany; Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany
| | - Brandon J McMurray
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada M5G 0A4, Canada
| | | | - Minze Xu
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany
| | - Kerstin Zühlke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Michael Russwurm
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät MA N1, Ruhr-Universität Bochum, Bochum, Germany
| | - Theda U P Bartolomaeus
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany; Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany
| | - Reika Langanki
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Fatimunnisa Qadri
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Andreas Patzak
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany
| | - Sofia K Forslund
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany; Berlin Institute of Health (BIH), Berlin, Germany; European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany
| | - Sylvia Bähring
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany; Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany
| | - Tatiana Borodina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Pontus B Persson
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany
| | - Philipp G Maass
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada M5G 0A4, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, M5S 1A8, Canada
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Germany; Institute for Biology, University of Lübeck, Germany
| | - Enno Klussmann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
| |
Collapse
|
5
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. Author Correction: A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023:10.1038/s41593-023-01328-1. [PMID: 37072562 DOI: 10.1038/s41593-023-01328-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Affiliation(s)
- Joanes Grandjean
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands.
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
| | - Gabriel Desrosiers-Gregoire
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada
| | - Cynthia Anckaerts
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Diego Angeles-Valdez
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Fadi Ayad
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - David A Barrière
- UMR INRAE/CNRS 7247 Physiologie des Comportements et de la Reproduction, Physiologie de la reproduction et des comportements, Centre de recherche INRAE de Nouzilly, Tours, France
| | - Ines Blockx
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Aleksandra Bortel
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Margaret Broadwater
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Beatriz M Cardoso
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Marina Célestine
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Jorge E Chavez-Negrete
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Sangcheon Choi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Emma Christiaen
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Perrin Clavijo
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Luis Colon-Perez
- Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Samuel Cramer
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Tolomeo Daniele
- Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Elaine Dempsey
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Yujian Diao
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Laboratory for Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Arno Doelemeyer
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - David Dopfel
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Lenka Dvořáková
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Claudia Falfán-Melgoza
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Francisca F Fernandes
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Caitlin F Fowler
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
| | - Antonio Fuentes-Ibañez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Clément M Garin
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Eveline Gelderman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Carla E M Golden
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Chao C G Guo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Marloes J A G Henckens
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Lauren A Hennessy
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Peter Herman
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Nita Hofwijks
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Corey Horien
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Tudor M Ionescu
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Jolyon Jones
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Johannes Kaesser
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Eugene Kim
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Henriette Lambers
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Alberto Lazari
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Sung-Ho Lee
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amanda Lillywhite
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
| | - Yikang Liu
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Yanyan Y Liu
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Alejandra López-Castro
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Xavier López-Gil
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Zilu Ma
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Eilidh MacNicol
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Dan Madularu
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Center for Translational Neuroimaging, Northeastern University, Boston, MA, USA
| | - Francesca Mandino
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Sabina Marciano
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Matthew J McAuslan
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
| | - Patrick McCunn
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Alison McIntosh
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Xianzong Meng
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Lisa Meyer-Baese
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Stephan Missault
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Federico Moro
- Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Daphne M P Naessens
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Laura J Nava-Gomez
- Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, México
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | - Hiroi Nonaka
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Juan J Ortiz
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jaakko Paasonen
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Lore M Peeters
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Mickaël Pereira
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Pablo D Perez
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Marjory Pompilus
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Malcolm Prior
- School of Medicine, University of Nottingham, Nottingham, UK
| | | | - Henning M Reimann
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Jonathan Reinwald
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Rodrigo Triana Del Rio
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | - Alejandro Rivera-Olvera
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | | | - Gabriele Russo
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
| | - Tobias J Rutten
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Rie Ryoke
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Markus Sack
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Piergiorgio Salvan
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Basavaraju G Sanganahalli
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Aileen Schroeter
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bhedita J Seewoo
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | | | - Aline Seuwen
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bowen Shi
- iHuman Institute, ShanghaiTech University, Shanghai, China
| | - Nikoloz Sirmpilatze
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Joanna A B Smith
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Corrie Smith
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Filip Sobczak
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Petteri J Stenroos
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Milou Straathof
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Sandra Strobelt
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Akira Sumiyoshi
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- National Institutes for Quantum Science and Technology, Chiba, Japan
| | - Kengo Takahashi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Maria E Torres-García
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Raul Tudela
- Group of Biomedical Imaging, Consorcio Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), University of Barcelona, Barcelona, Spain
| | - Monica van den Berg
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Kajo van der Marel
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Aran T B van Hout
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Roberta Vertullo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Benjamin Vidal
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Roël M Vrooman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Victora X Wang
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Isabel Wank
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - David J G Watson
- School of Life Sciences, University of Nottingham, Nottingham, UK
| | - Ting Yin
- Animal Imaging and Technology Section, Center for Biomedical Imaging, École polytechnique fédérale de Lausanne, Lausanne, Switzerland
| | - Yongzhi Zhang
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Stefan Zurbruegg
- Neurosciences Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Sophie Achard
- Inria, University Grenoble Alpes, CNRS, Grenoble, France
| | - Sarael Alcauter
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Dorothee P Auer
- School of Medicine, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Emmanuel L Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Jürgen Baudewig
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
| | - Christian F Beckmann
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Nicolau Beckmann
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Erwin L A Blezer
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | | | - Susann Boretius
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Sandrine Bouvard
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Eike Budinger
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
- Center for Behavioral Brain Sciences, Magdeburg, Germany
| | - Joseph D Buxbaum
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Diana Cash
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Victoria Chapman
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Kai-Hsiang Chuang
- Queensland Brain Institute and Centre for Advanced Imaging, University of Queensland, St. Lucia, QLD, Australia
| | | | - Bram F Coolen
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Jeffrey W Dalley
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Marc Dhenain
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Rick M Dijkhuizen
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Oscar Esteban
- Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Cornelius Faber
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Marcelo Febo
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Kirk W Feindel
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | - Gianluigi Forloni
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Jérémie Fouquet
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
| | - Eduardo A Garza-Villarreal
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Natalia Gass
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Jeffrey C Glennon
- Conway Institute of Biomedical and Biomolecular Sciences, School of Medicine, University College Dublin, Dublin, Ireland
| | - Alessandro Gozzi
- Functional Neuroimaging Laboratory, Center for Neuroscience and Cognitive Systems, Istituto Italiano di Tecnologia, Rovereto, Italy
| | - Olli Gröhn
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Andrew Harkin
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Arend Heerschap
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Xavier Helluy
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
- Department of Biopsychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany
| | - Kristina Herfert
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Judith R Homberg
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Danielle J Houwing
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Fahmeed Hyder
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | | | - Ileana O Jelescu
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Heidi Johansen-Berg
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gen Kaneko
- School of Arts & Sciences, University of Houston-Victoria, Victoria, TX, USA
| | - Ryuta Kawashima
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Shella D Keilholz
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Georgios A Keliris
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Clare Kelly
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- School of Psychology, Trinity College Dublin, Dublin, Ireland
- Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Christian Kerskens
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Trinity Centre for Biomedical Engineering, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Jibran Y Khokhar
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Peter C Kind
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
- Centre for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine, Bangalore, India
| | | | - Jason P Lerch
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- Department of Medical Biophysics, University of Toronto, Toronto, QC, Canada
| | - Monica A López-Hidalgo
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | | | - Fabien Marchand
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - Rogier B Mars
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gerardo Marsella
- Animal Care Unit, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Edoardo Micotti
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Emma Muñoz-Moreno
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Jamie Near
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Physical Sciences Platform, Sunnybrook Research Institute, Toronto, QC, Canada
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Willem M Otte
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
- Department of Pediatric Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Patricia Pais-Roldán
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine, Forschungszentrum Juelich, Juelich, Germany
| | - Wen-Ju Pan
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Roberto A Prado-Alcalá
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Gina L Quirarte
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jennifer Rodger
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Tim Rosenow
- Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Crawley, WA, Australia
| | - Cassandra Sampaio-Baptista
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- School of Psychology and Neuroscience, University of Glasgow, Glasgow, UK
| | - Alexander Sartorius
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Stephen J Sawiak
- Translational Neuroimaging Laboratory, Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Tom W J Scheenen
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
| | - Noam Shemesh
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Yen-Yu Ian Shih
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amir Shmuel
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- Department of Physiology, McGill University, Montreal, QC, Canada
| | - Guadalupe Soria
- Laboratory of Surgical Neuroanatomy, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Ron Stoop
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | | | - Sally M Till
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Nick Todd
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Annemie Van Der Linden
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Annette van der Toorn
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Geralda A F van Tilborg
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Christian Vanhove
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Andor Veltien
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marleen Verhoye
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Lydia Wachsmuth
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Wolfgang Weber-Fahr
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Patricia Wenk
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
| | - Xin Yu
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
| | - Valerio Zerbi
- Neuro-X Institute, School of Engineering (STI), EPFL, Lausanne, Switzerland
- Centre for Biomedical Imaging (CIBM), Lausanne, Switzerland
| | - Nanyin Zhang
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Baogui B Zhang
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Luc Zimmer
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
- CERMEP - Imagerie du vivant, Lyon, France
- Hospices Civils de Lyon, Lyon, France
| | - Gabriel A Devenyi
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - M Mallar Chakravarty
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Andreas Hess
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
6
|
Grandjean J, Desrosiers-Gregoire G, Anckaerts C, Angeles-Valdez D, Ayad F, Barrière DA, Blockx I, Bortel A, Broadwater M, Cardoso BM, Célestine M, Chavez-Negrete JE, Choi S, Christiaen E, Clavijo P, Colon-Perez L, Cramer S, Daniele T, Dempsey E, Diao Y, Doelemeyer A, Dopfel D, Dvořáková L, Falfán-Melgoza C, Fernandes FF, Fowler CF, Fuentes-Ibañez A, Garin CM, Gelderman E, Golden CEM, Guo CCG, Henckens MJAG, Hennessy LA, Herman P, Hofwijks N, Horien C, Ionescu TM, Jones J, Kaesser J, Kim E, Lambers H, Lazari A, Lee SH, Lillywhite A, Liu Y, Liu YY, López-Castro A, López-Gil X, Ma Z, MacNicol E, Madularu D, Mandino F, Marciano S, McAuslan MJ, McCunn P, McIntosh A, Meng X, Meyer-Baese L, Missault S, Moro F, Naessens DMP, Nava-Gomez LJ, Nonaka H, Ortiz JJ, Paasonen J, Peeters LM, Pereira M, Perez PD, Pompilus M, Prior M, Rakhmatullin R, Reimann HM, Reinwald J, Del Rio RT, Rivera-Olvera A, Ruiz-Pérez D, Russo G, Rutten TJ, Ryoke R, Sack M, Salvan P, Sanganahalli BG, Schroeter A, Seewoo BJ, Selingue E, Seuwen A, Shi B, Sirmpilatze N, Smith JAB, Smith C, Sobczak F, Stenroos PJ, Straathof M, Strobelt S, Sumiyoshi A, Takahashi K, Torres-García ME, Tudela R, van den Berg M, van der Marel K, van Hout ATB, Vertullo R, Vidal B, Vrooman RM, Wang VX, Wank I, Watson DJG, Yin T, Zhang Y, Zurbruegg S, Achard S, Alcauter S, Auer DP, Barbier EL, Baudewig J, Beckmann CF, Beckmann N, Becq GJPC, Blezer ELA, Bolbos R, Boretius S, Bouvard S, Budinger E, Buxbaum JD, Cash D, Chapman V, Chuang KH, Ciobanu L, Coolen BF, Dalley JW, Dhenain M, Dijkhuizen RM, Esteban O, Faber C, Febo M, Feindel KW, Forloni G, Fouquet J, Garza-Villarreal EA, Gass N, Glennon JC, Gozzi A, Gröhn O, Harkin A, Heerschap A, Helluy X, Herfert K, Heuser A, Homberg JR, Houwing DJ, Hyder F, Ielacqua GD, Jelescu IO, Johansen-Berg H, Kaneko G, Kawashima R, Keilholz SD, Keliris GA, Kelly C, Kerskens C, Khokhar JY, Kind PC, Langlois JB, Lerch JP, López-Hidalgo MA, Manahan-Vaughan D, Marchand F, Mars RB, Marsella G, Micotti E, Muñoz-Moreno E, Near J, Niendorf T, Otte WM, Pais-Roldán P, Pan WJ, Prado-Alcalá RA, Quirarte GL, Rodger J, Rosenow T, Sampaio-Baptista C, Sartorius A, Sawiak SJ, Scheenen TWJ, Shemesh N, Shih YYI, Shmuel A, Soria G, Stoop R, Thompson GJ, Till SM, Todd N, Van Der Linden A, van der Toorn A, van Tilborg GAF, Vanhove C, Veltien A, Verhoye M, Wachsmuth L, Weber-Fahr W, Wenk P, Yu X, Zerbi V, Zhang N, Zhang BB, Zimmer L, Devenyi GA, Chakravarty MM, Hess A. A consensus protocol for functional connectivity analysis in the rat brain. Nat Neurosci 2023; 26:673-681. [PMID: 36973511 PMCID: PMC10493189 DOI: 10.1038/s41593-023-01286-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Accepted: 02/15/2023] [Indexed: 03/29/2023]
Abstract
Task-free functional connectivity in animal models provides an experimental framework to examine connectivity phenomena under controlled conditions and allows for comparisons with data modalities collected under invasive or terminal procedures. Currently, animal acquisitions are performed with varying protocols and analyses that hamper result comparison and integration. Here we introduce StandardRat, a consensus rat functional magnetic resonance imaging acquisition protocol tested across 20 centers. To develop this protocol with optimized acquisition and processing parameters, we initially aggregated 65 functional imaging datasets acquired from rats across 46 centers. We developed a reproducible pipeline for analyzing rat data acquired with diverse protocols and determined experimental and processing parameters associated with the robust detection of functional connectivity across centers. We show that the standardized protocol enhances biologically plausible functional connectivity patterns relative to previous acquisitions. The protocol and processing pipeline described here is openly shared with the neuroimaging community to promote interoperability and cooperation toward tackling the most important challenges in neuroscience.
Collapse
Affiliation(s)
- Joanes Grandjean
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands.
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
| | - Gabriel Desrosiers-Gregoire
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Integrated Program in Neuroscience, McGill University, Montreal, QC, Canada
| | - Cynthia Anckaerts
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Diego Angeles-Valdez
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Fadi Ayad
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - David A Barrière
- UMR INRAE/CNRS 7247 Physiologie des Comportements et de la Reproduction, Physiologie de la reproduction et des comportements, Centre de recherche INRAE de Nouzilly, Tours, France
| | - Ines Blockx
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Aleksandra Bortel
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Margaret Broadwater
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Beatriz M Cardoso
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Marina Célestine
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Jorge E Chavez-Negrete
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Sangcheon Choi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Emma Christiaen
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Perrin Clavijo
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Luis Colon-Perez
- Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - Samuel Cramer
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Tolomeo Daniele
- Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Elaine Dempsey
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Yujian Diao
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Laboratory for Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Arno Doelemeyer
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - David Dopfel
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Lenka Dvořáková
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Claudia Falfán-Melgoza
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Francisca F Fernandes
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Caitlin F Fowler
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
| | - Antonio Fuentes-Ibañez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Clément M Garin
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Eveline Gelderman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Carla E M Golden
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Chao C G Guo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Marloes J A G Henckens
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Department of Neuroscience and Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Lauren A Hennessy
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Peter Herman
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Nita Hofwijks
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Corey Horien
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Tudor M Ionescu
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Jolyon Jones
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Johannes Kaesser
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Eugene Kim
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Henriette Lambers
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Alberto Lazari
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Sung-Ho Lee
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amanda Lillywhite
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
| | - Yikang Liu
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Yanyan Y Liu
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Alejandra López-Castro
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Xavier López-Gil
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Zilu Ma
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Eilidh MacNicol
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Dan Madularu
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Center for Translational Neuroimaging, Northeastern University, Boston, MA, USA
| | - Francesca Mandino
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Sabina Marciano
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Matthew J McAuslan
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
| | - Patrick McCunn
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Alison McIntosh
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Xianzong Meng
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Lisa Meyer-Baese
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Stephan Missault
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Federico Moro
- Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of NeuroscienceIstituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Daphne M P Naessens
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Laura J Nava-Gomez
- Facultad de Medicina, Universidad Autónoma de Querétaro, Querétaro, México
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | - Hiroi Nonaka
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Juan J Ortiz
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jaakko Paasonen
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Lore M Peeters
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Mickaël Pereira
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Pablo D Perez
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Marjory Pompilus
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Malcolm Prior
- School of Medicine, University of Nottingham, Nottingham, UK
| | | | - Henning M Reimann
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Jonathan Reinwald
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Rodrigo Triana Del Rio
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | - Alejandro Rivera-Olvera
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | | | - Gabriele Russo
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
| | - Tobias J Rutten
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Rie Ryoke
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Markus Sack
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Piergiorgio Salvan
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Basavaraju G Sanganahalli
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | - Aileen Schroeter
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bhedita J Seewoo
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | | | - Aline Seuwen
- Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
| | - Bowen Shi
- iHuman Institute, ShanghaiTech University, Shanghai, China
| | - Nikoloz Sirmpilatze
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Joanna A B Smith
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Corrie Smith
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Filip Sobczak
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Petteri J Stenroos
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Milou Straathof
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Sandra Strobelt
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - Akira Sumiyoshi
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- National Institutes for Quantum Science and Technology, Chiba, Japan
| | - Kengo Takahashi
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Graduate Training Centre of Neuroscience, International Max Planck Research School, University of Tuebingen, Tuebingen, Germany
| | - Maria E Torres-García
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Raul Tudela
- Group of Biomedical Imaging, Consorcio Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), University of Barcelona, Barcelona, Spain
| | - Monica van den Berg
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Kajo van der Marel
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Aran T B van Hout
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Roberta Vertullo
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Benjamin Vidal
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Roël M Vrooman
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Victora X Wang
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Isabel Wank
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| | - David J G Watson
- School of Life Sciences, University of Nottingham, Nottingham, UK
| | - Ting Yin
- Animal Imaging and Technology Section, Center for Biomedical Imaging, École polytechnique fédérale de Lausanne, Lausanne, Switzerland
| | - Yongzhi Zhang
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Stefan Zurbruegg
- Neurosciences Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Sophie Achard
- Inria, University Grenoble Alpes, CNRS, Grenoble, France
| | - Sarael Alcauter
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Dorothee P Auer
- School of Medicine, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Emmanuel L Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France
| | - Jürgen Baudewig
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
| | - Christian F Beckmann
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Nicolau Beckmann
- Musculoskeletal Diseases Department, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Erwin L A Blezer
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | | | - Susann Boretius
- Functional Imaging Laboratory, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany
- Faculty of Biology and Psychology, Georg-August University of Göttingen, Göttingen, Germany
- DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
| | - Sandrine Bouvard
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
| | - Eike Budinger
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
- Center for Behavioral Brain Sciences, Magdeburg, Germany
| | - Joseph D Buxbaum
- Seaver Autism Center for Research & Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
| | - Diana Cash
- Biomarker Research And Imaging in Neuroscience (BRAIN) Centre, Department of Neuroimaging King's College London, London, UK
| | - Victoria Chapman
- School of Life Sciences, University of Nottingham, Nottingham, UK
- Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK
- NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Kai-Hsiang Chuang
- Queensland Brain Institute and Centre for Advanced Imaging, University of Queensland, St. Lucia, QLD, Australia
| | | | - Bram F Coolen
- Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Jeffrey W Dalley
- Department of Psychology, University of Cambridge, Cambridge, UK
| | - Marc Dhenain
- Laboratoire des Maladies Neurodégénératives, Molecular Imaging Research Center (MIRCen), Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), CNRS, Fontenay-aux-Roses, France
| | - Rick M Dijkhuizen
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Oscar Esteban
- Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Cornelius Faber
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Marcelo Febo
- Febo Laboratory, Department of Psychiatry, University of Florida, Gainesville, FL, USA
| | - Kirk W Feindel
- Centre for Microscopy, Characterisation & Analysis, Research Infrastructure Centres, University of Western Australia, Nedlands, WA, Australia
| | - Gianluigi Forloni
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Jérémie Fouquet
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
| | - Eduardo A Garza-Villarreal
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, Mexico
| | - Natalia Gass
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Jeffrey C Glennon
- Conway Institute of Biomedical and Biomolecular Sciences, School of Medicine, University College Dublin, Dublin, Ireland
| | - Alessandro Gozzi
- Functional Neuroimaging Laboratory, Center for Neuroscience and Cognitive Systems, Istituto Italiano di Tecnologia, Rovereto, Italy
| | - Olli Gröhn
- Biomedical Imaging Unit, A.I.V. Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Andrew Harkin
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - Arend Heerschap
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Xavier Helluy
- Department of Neurophysiology, Medical Faculty, Ruhr University Bochum, Bochum, Germany
- Department of Biopsychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany
| | - Kristina Herfert
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tuebingen, Tuebingen, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Judith R Homberg
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Danielle J Houwing
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
| | - Fahmeed Hyder
- Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
- Quantitative Neuroscience with Magnetic Resonance (QNMR) Core Center, Yale University School of Medicine, New Haven, CT, USA
| | | | - Ileana O Jelescu
- CIBM Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Heidi Johansen-Berg
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gen Kaneko
- School of Arts & Sciences, University of Houston-Victoria, Victoria, TX, USA
| | - Ryuta Kawashima
- Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - Shella D Keilholz
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Georgios A Keliris
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Clare Kelly
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- School of Psychology, Trinity College Dublin, Dublin, Ireland
- Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Christian Kerskens
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Trinity Centre for Biomedical Engineering, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Jibran Y Khokhar
- Khokhar Lab, Department of Anatomy and Cell Biology, Western University, London, ON, Canada
| | - Peter C Kind
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
- Centre for Brain Development and Repair, Institute for Stem Cell Biology and Regenerative Medicine, Bangalore, India
| | | | - Jason P Lerch
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- Department of Medical Biophysics, University of Toronto, Toronto, QC, Canada
| | - Monica A López-Hidalgo
- Escuela Nacional de Estudios Superiores, Juriquilla, Universidad Nacional Autónoma de México, Querétaro, México
| | | | - Fabien Marchand
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - Rogier B Mars
- Donders Institute for Brain, Behaviour, and Cognition, Radboud University, Nijmegen, The Netherlands
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
| | - Gerardo Marsella
- Animal Care Unit, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Edoardo Micotti
- Biology of Neurodogenerative Disorders, Department of Neuroscience Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Milan, Italy
| | - Emma Muñoz-Moreno
- Magnetic Imaging Resonance Core Facility, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Jamie Near
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Physical Sciences Platform, Sunnybrook Research Institute, Toronto, QC, Canada
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Willem M Otte
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
- Department of Pediatric Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Patricia Pais-Roldán
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Medical Imaging Physics (INM-4), Institute of Neuroscience and Medicine, Forschungszentrum Juelich, Juelich, Germany
| | - Wen-Ju Pan
- Department of Biomedical Engineering, Emory University/Georgia Institute of Technology, Atlanta, GA, USA
| | - Roberto A Prado-Alcalá
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Gina L Quirarte
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriquilla, Querétaro, México
| | - Jennifer Rodger
- Experimental and Regenerative Neurosciences, School of Biological Sciences, University of Western Australia, Crawley, WA, Australia
- Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia
| | - Tim Rosenow
- Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Crawley, WA, Australia
| | - Cassandra Sampaio-Baptista
- Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- School of Psychology and Neuroscience, University of Glasgow, Glasgow, UK
| | - Alexander Sartorius
- Translational Imaging, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Stephen J Sawiak
- Translational Neuroimaging Laboratory, Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Tom W J Scheenen
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
| | - Noam Shemesh
- Preclinical MRI, Champalimaud Research, Champalimaud Centre for the Unknown, Lisbon, Portugal
| | - Yen-Yu Ian Shih
- Center for Animal MRI, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Amir Shmuel
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, McGill University, Montreal, QC, Canada
- Montreal Neurological Institute, McGill University, Montreal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- Department of Physiology, McGill University, Montreal, QC, Canada
| | - Guadalupe Soria
- Laboratory of Surgical Neuroanatomy, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Ron Stoop
- Psychiatric neurosciences, Center for Psychiatric Neuroscience, Lausanne University and University Hospital Center, Unicentre, Lausanne, Switzerland
| | | | - Sally M Till
- Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK
- Patrick Wild Centre, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Nick Todd
- Focused Ultrasound Laboratory, Department of Radiology Brigham and Women's Hospital, Boston, MA, USA
| | - Annemie Van Der Linden
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Annette van der Toorn
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Geralda A F van Tilborg
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht & Utrecht University, Utrecht, The Netherlands
| | - Christian Vanhove
- Institute Biomedical Technology (IBiTech), Electronics and Information Systems (ELIS), Ghent University, Gent, Belgium
| | - Andor Veltien
- Department for Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Marleen Verhoye
- Bio-imaging Lab, University of Antwerp, Antwerp, Belgium
- µNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Lydia Wachsmuth
- Experimental Magnetic Resonance Group, Clinic of Radiology, University of Münster, Münster, Germany
| | - Wolfgang Weber-Fahr
- Translational Imaging, Department of Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Mannheim, Germany
| | - Patricia Wenk
- Combinatorial NeuroImaging Core Facility, Leibniz Institute for Neurobiology, Magdeburg, Germany
| | - Xin Yu
- Translational Neuroimaging and Neural Control Group, High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
| | - Valerio Zerbi
- Neuro-X Institute, School of Engineering (STI), EPFL, Lausanne, Switzerland
- Centre for Biomedical Imaging (CIBM), Lausanne, Switzerland
| | - Nanyin Zhang
- Translational Neuroimaging and Systems Neuroscience Lab, Biomedical Engineering, Pennsylvania State University, University Park, PA, USA
| | - Baogui B Zhang
- Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China
| | - Luc Zimmer
- Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, INSERM, CNRS, Lyon, France
- CERMEP - Imagerie du vivant, Lyon, France
- Hospices Civils de Lyon, Lyon, France
| | - Gabriel A Devenyi
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - M Mallar Chakravarty
- Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada
- Biological and Biomedical Engineering, McGill University, Montreal, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
| | - Andreas Hess
- Institute of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
7
|
Freiberg F, Thakkar M, Hamann W, Lopez Carballo J, Jüttner R, Voss FK, Becher PM, Westermann D, Tschöpe C, Heuser A, Rocks O, Fischer R, Gotthardt M. CAR links hypoxia signaling to improved survival after myocardial infarction. Exp Mol Med 2023; 55:643-652. [PMID: 36941462 PMCID: PMC10073142 DOI: 10.1038/s12276-023-00963-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 11/08/2022] [Accepted: 12/25/2022] [Indexed: 03/23/2023] Open
Abstract
The coxsackievirus and adenovirus receptor (CAR) mediates homo- and heterotopic interactions between neighboring cardiomyocytes at the intercalated disc. CAR is upregulated in the hypoxic areas surrounding myocardial infarction (MI). To elucidate whether CAR contributes to hypoxia signaling and MI pathology, we used a gain- and loss-of-function approach in transfected HEK293 cells, H9c2 cardiomyocytes and CAR knockout mice. CAR overexpression increased RhoA activity, HIF-1α expression and cell death in response to chemical and physical hypoxia. In vivo, we subjected cardiomyocyte-specific CAR knockout (KO) and wild-type mice (WT) to coronary artery ligation. Survival was drastically improved in KO mice with largely preserved cardiac function as determined by echocardiography. Histological analysis revealed a less fibrotic, more compact lesion. Thirty days after MI, there was no compensatory hypertrophy or reduced cardiac output in hearts from CAR KO mice, in contrast to control mice with increased heart weight and reduced ejection fraction as signs of the underlying pathology. Based on these findings, we suggest CAR as a therapeutic target for the improved future treatment or prevention of myocardial infarction.
Collapse
Affiliation(s)
- Fabian Freiberg
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Meghna Thakkar
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Wiebke Hamann
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Jacobo Lopez Carballo
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Rene Jüttner
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Felizia K Voss
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Peter M Becher
- Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany
- DZHK Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | - Dirk Westermann
- Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany
- DZHK Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | - Carsten Tschöpe
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- BCRT (Berlin-Brandenburg Center for Regenerative Therapies), Berlin, Germany
| | - Arnd Heuser
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Oliver Rocks
- Spatiotemporal Control of Rho GTPase Signaling, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Robert Fischer
- Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Michael Gotthardt
- Translational Cardiology and Functional Genomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
- Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
| |
Collapse
|
8
|
Winkler W, Farré Díaz C, Blanc E, Napieczynska H, Langner P, Werner M, Walter B, Wollert-Wulf B, Yasuda T, Heuser A, Beule D, Mathas S, Anagnostopoulos I, Rosenwald A, Rajewsky K, Janz M. Mouse models of human multiple myeloma subgroups. Proc Natl Acad Sci U S A 2023; 120:e2219439120. [PMID: 36853944 PMCID: PMC10013859 DOI: 10.1073/pnas.2219439120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 01/26/2023] [Indexed: 03/01/2023] Open
Abstract
Multiple myeloma (MM), a tumor of germinal center (GC)-experienced plasma cells, comprises distinct genetic subgroups, such as the t(11;14)/CCND1 and the t(4;14)/MMSET subtype. We have generated genetically defined, subgroup-specific MM models by the GC B cell-specific coactivation of mouse Ccnd1 or MMSET with a constitutively active Ikk2 mutant, mimicking the secondary NF-κB activation frequently seen in human MM. Ccnd1/Ikk2ca and MMSET/Ikk2ca mice developed a pronounced, clonally restricted plasma cell outgrowth with age, accompanied by serum M spikes, bone marrow insufficiency, and bone lesions. The transgenic plasma cells could be propagated in vivo and showed distinct transcriptional profiles, resembling their human MM counterparts. Thus, we show that targeting the expression of genes involved in MM subgroup-specific chromosomal translocations into mouse GC B cells translates into distinct MM-like diseases that recapitulate key features of the human tumors, opening the way to a better understanding of the pathogenesis and therapeutic vulnerabilities of different MM subgroups.
Collapse
Affiliation(s)
- Wiebke Winkler
- Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Carlota Farré Díaz
- Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Eric Blanc
- Core Unit Bioinformatics, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin10117, Germany
| | - Hanna Napieczynska
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
| | - Patrick Langner
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
| | - Marvin Werner
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Barbara Walter
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Brigitte Wollert-Wulf
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Tomoharu Yasuda
- Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
| | - Arnd Heuser
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
| | - Dieter Beule
- Core Unit Bioinformatics, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin10117, Germany
| | - Stephan Mathas
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| | - Ioannis Anagnostopoulos
- Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken, Würzburg97080, Germany
| | - Andreas Rosenwald
- Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken, Würzburg97080, Germany
| | - Klaus Rajewsky
- Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
| | - Martin Janz
- Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin13125, Germany
- Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité – Universitätsmedizin Berlin, Berlin13125, Germany
- Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, Berlin13125, Germany
| |
Collapse
|
9
|
Ercu M, Mücke MB, Pallien T, Markó L, Sholokh A, Schächterle C, Aydin A, Kidd A, Walter S, Esmati Y, McMurray BJ, Lato DF, Yumi Sunaga-Franze D, Dierks PH, Flores BIM, Walker-Gray R, Gong M, Merticariu C, Zühlke K, Russwurm M, Liu T, Batolomaeus TUP, Pautz S, Schelenz S, Taube M, Napieczynska H, Heuser A, Eichhorst J, Lehmann M, Miller DC, Diecke S, Qadri F, Popova E, Langanki R, Movsesian MA, Herberg FW, Forslund SK, Müller DN, Borodina T, Maass PG, Bähring S, Hübner N, Bader M, Klussmann E. Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage. Circulation 2022; 146:1758-1778. [PMID: 36259389 DOI: 10.1161/circulationaha.122.060210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 08/24/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Phosphodiesterase 3A (PDE3A) gain-of-function mutations cause hypertension with brachydactyly (HTNB) and lead to stroke. Increased peripheral vascular resistance, rather than salt retention, is responsible. It is surprising that the few patients with HTNB examined so far did not develop cardiac hypertrophy or heart failure. We hypothesized that, in the heart, PDE3A mutations could be protective. METHODS We studied new patients. CRISPR-Cas9-engineered rat HTNB models were phenotyped by telemetric blood pressure measurements, echocardiography, microcomputed tomography, RNA-sequencing, and single nuclei RNA-sequencing. Human induced pluripotent stem cells carrying PDE3A mutations were established, differentiated to cardiomyocytes, and analyzed by Ca2+ imaging. We used Förster resonance energy transfer and biochemical assays. RESULTS We identified a new PDE3A mutation in a family with HTNB. It maps to exon 13 encoding the enzyme's catalytic domain. All hitherto identified HTNB PDE3A mutations cluster in exon 4 encoding a region N-terminally from the catalytic domain of the enzyme. The mutations were recapitulated in rat models. Both exon 4 and 13 mutations led to aberrant phosphorylation, hyperactivity, and increased PDE3A enzyme self-assembly. The left ventricles of our patients with HTNB and the rat models were normal despite preexisting hypertension. A catecholamine challenge elicited cardiac hypertrophy in HTNB rats only to the level of wild-type rats and improved the contractility of the mutant hearts, compared with wild-type rats. The β-adrenergic system, phosphodiesterase activity, and cAMP levels in the mutant hearts resembled wild-type hearts, whereas phospholamban phosphorylation was decreased in the mutants. In our induced pluripotent stem cell cardiomyocyte models, the PDE3A mutations caused adaptive changes of Ca2+ cycling. RNA-sequencing and single nuclei RNA-sequencing identified differences in mRNA expression between wild-type and mutants, affecting, among others, metabolism and protein folding. CONCLUSIONS Although in vascular smooth muscle, PDE3A mutations cause hypertension, they confer protection against hypertension-induced cardiac damage in hearts. Nonselective PDE3A inhibition is a final, short-term option in heart failure treatment to increase cardiac cAMP and improve contractility. Our data argue that mimicking the effect of PDE3A mutations in the heart rather than nonselective PDE3 inhibition is cardioprotective in the long term. Our findings could facilitate the search for new treatments to prevent hypertension-induced cardiac damage.
Collapse
Affiliation(s)
- Maria Ercu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Michael B Mücke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Tamara Pallien
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Lajos Markó
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Anastasiia Sholokh
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Carolin Schächterle
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Atakan Aydin
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Alexa Kidd
- Clinical Genetics Ltd, Christchurch, New Zealand (A.K.)
| | | | - Yasmin Esmati
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Brandon J McMurray
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
| | - Daniella F Lato
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
| | - Daniele Yumi Sunaga-Franze
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Philip H Dierks
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Barbara Isabel Montesinos Flores
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Ryan Walker-Gray
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Maolian Gong
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Claudia Merticariu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Kerstin Zühlke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Michael Russwurm
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät MA N1, Ruhr-Universität Bochum, Germany (M.R.)
| | - Tiannan Liu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Theda U P Batolomaeus
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Sabine Pautz
- Department of Biochemistry, University of Kassel, Germany (S.P., F.W.H.)
| | - Stefanie Schelenz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Martin Taube
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Hanna Napieczynska
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Jenny Eichhorst
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L.)
| | - Martin Lehmann
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L.)
| | - Duncan C Miller
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| | - Sebastian Diecke
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Berlin Institute of Health (BIH), Germany (S.D., S.K.F.)
| | - Fatimunnisa Qadri
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Elena Popova
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Reika Langanki
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | | | | | - Sofia K Forslund
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
- Berlin Institute of Health (BIH), Germany (S.D., S.K.F.)
- European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, Germany (S.K.F.)
| | - Dominik N Müller
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Tatiana Borodina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
| | - Philipp G Maass
- Genetics and Genome Biology Program, SickKids Research Institute, Toronto, ON, Canada (B.J.M., D.F.L., P.G.M.)
- Department of Molecular Genetics, University of Toronto, ON, Canada (P.G.M.)
| | - Sylvia Bähring
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Experimental and Clinical Research Center, a cooperation between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Universitätsmedizin Berlin, Germany (L.M., Y.E., M.G., T.U.P.B., S.K.F., D.N.M., S.B.)
| | - Norbert Hübner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany (M.B.M., L.M., A.S., Y.E., T.U.P.B., S.K.F., S.B., N.H., M.B.)
- Institute for Biology, University of Lübeck, Germany (M.B.)
| | - Enno Klussmann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.)
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (M.E., M.B.M., T.P., L.M., A.S., Y.E., T.U.P.B., D.C.M., S.D., S.K.F., D.N.M., N.H., M.B., E.K.)
| |
Collapse
|
10
|
Azarnia Tehran D, Kochlamazashvili G, Pampaloni NP, Sposini S, Shergill JK, Lehmann M, Pashkova N, Schmidt C, Löwe D, Napieczynska H, Heuser A, Plested AJR, Perrais D, Piper RC, Haucke V, Maritzen T. Selective endocytosis of Ca 2+-permeable AMPARs by the Alzheimer's disease risk factor CALM bidirectionally controls synaptic plasticity. Sci Adv 2022; 8:eabl5032. [PMID: 35613266 PMCID: PMC9132451 DOI: 10.1126/sciadv.abl5032] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Accepted: 04/05/2022] [Indexed: 06/15/2023]
Abstract
AMPA-type glutamate receptors (AMPARs) mediate fast excitatory neurotransmission, and the plastic modulation of their surface levels determines synaptic strength. AMPARs of different subunit compositions fulfill distinct roles in synaptic long-term potentiation (LTP) and depression (LTD) to enable learning. Largely unknown endocytic mechanisms mediate the subunit-selective regulation of the surface levels of GluA1-homomeric Ca2+-permeable (CP) versus heteromeric Ca2+-impermeable (CI) AMPARs. Here, we report that the Alzheimer's disease risk factor CALM controls the surface levels of CP-AMPARs and thereby reciprocally regulates LTP and LTD in vivo to modulate learning. We show that CALM selectively facilitates the endocytosis of ubiquitinated CP-AMPARs via a mechanism that depends on ubiquitin recognition by its ANTH domain but is independent of clathrin. Our data identify CALM and related ANTH domain-containing proteins as the core endocytic machinery that determines the surface levels of CP-AMPARs to bidirectionally control synaptic plasticity and modulate learning in the mammalian brain.
Collapse
Affiliation(s)
- Domenico Azarnia Tehran
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Gaga Kochlamazashvili
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Niccolò P. Pampaloni
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
- Institute of Biology, Cellular Biophysics, Humboldt Universität zu Berlin, 10115 Berlin, Germany
| | - Silvia Sposini
- University of Bordeaux, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France
- CNRS, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France
| | - Jasmeet Kaur Shergill
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
- Department of Nanophysiology, Technische Universität Kaiserslautern, Paul-Ehrlich-Strasse 23, 67663 Kaiserslautern, Germany
| | - Martin Lehmann
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Natalya Pashkova
- Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
| | - Claudia Schmidt
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Delia Löwe
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Hanna Napieczynska
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine, Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Arnd Heuser
- Animal Phenotyping, Max Delbrück Center for Molecular Medicine, Robert-Roessle-Straße 10, 13125 Berlin, Germany
| | - Andrew J. R. Plested
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
- Institute of Biology, Cellular Biophysics, Humboldt Universität zu Berlin, 10115 Berlin, Germany
- NeuroCure Cluster of Excellence, Charité Universitätsmedizin Berlin, Virchowweg 6, 10117 Berlin, Germany
| | - David Perrais
- University of Bordeaux, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France
- CNRS, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France
| | - Robert C. Piper
- Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
| | - Volker Haucke
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
- NeuroCure Cluster of Excellence, Charité Universitätsmedizin Berlin, Virchowweg 6, 10117 Berlin, Germany
- Freie Universität Berlin, Faculty of Biology, Chemistry and Pharmacy, 14195 Berlin, Germany
| | - Tanja Maritzen
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
- Department of Nanophysiology, Technische Universität Kaiserslautern, Paul-Ehrlich-Strasse 23, 67663 Kaiserslautern, Germany
| |
Collapse
|
11
|
Busch K, Kny M, Huang N, Klassert TE, Stock M, Hahn A, Graeger S, Todiras M, Schmidt S, Chamling B, Willenbrock M, Groß S, Biedenweg D, Heuser A, Scheidereit C, Butter C, Felix SB, Otto O, Luft FC, Slevogt H, Fielitz J. Inhibition of the NLRP3/IL-1β axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle 2021; 12:1653-1668. [PMID: 34472725 PMCID: PMC8718055 DOI: 10.1002/jcsm.12763] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 06/03/2021] [Accepted: 07/09/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Septic cardiomyopathy worsens the prognosis of critically ill patients. Clinical data suggest that interleukin-1β (IL-1β), activated by the NLRP3 inflammasome, compromises cardiac function. Whether or not deleting Nlrp3 would prevent cardiac atrophy and improve diastolic cardiac function in sepsis was unclear. Here, we investigated the role of NLRP3/IL-1β in sepsis-induced cardiomyopathy and cardiac atrophy. METHODS Male Nlrp3 knockout (KO) and wild-type (WT) mice were exposed to polymicrobial sepsis by caecal ligation and puncture (CLP) surgery (KO, n = 27; WT, n = 33) to induce septic cardiomyopathy. Sham-treated mice served as controls (KO, n = 11; WT, n = 16). Heart weights and morphology, echocardiography and analyses of gene and protein expression were used to evaluate septic cardiomyopathy and cardiac atrophy. IL-1β effects on primary and immortalized cardiomyocytes were investigated by morphological and molecular analyses. IonOptix and real-time deformability cytometry (RT-DC) analysis were used to investigate functional and mechanical effects of IL-1β on cardiomyocytes. RESULTS Heart morphology and echocardiography revealed preserved systolic (stroke volume: WT sham vs. WT CLP: 33.1 ± 7.2 μL vs. 24.6 ± 8.7 μL, P < 0.05; KO sham vs. KO CLP: 28.3 ± 8.1 μL vs. 29.9 ± 9.9 μL, n.s.; P < 0.05 vs. WT CLP) and diastolic (peak E wave velocity: WT sham vs. WT CLP: 750 ± 132 vs. 522 ± 200 mm/s, P < 0.001; KO sham vs. KO CLP: 709 ± 152 vs. 639 ± 165 mm/s, n.s.; P < 0.05 vs. WT CLP) cardiac function and attenuated cardiac (heart weight-tibia length ratio: WT CLP vs. WT sham: -26.6%, P < 0.05; KO CLP vs. KO sham: -3.3%, n.s.; P < 0.05 vs. WT CLP) and cardiomyocyte atrophy in KO mice during sepsis. IonOptix measurements showed that IL-1β decreased contractility (cell shortening: IL-1β: -15.4 ± 2.3%, P < 0.001 vs. vehicle, IL-1RA: -6.1 ± 3.3%, P < 0.05 vs. IL-1β) and relaxation of adult rat ventricular cardiomyocytes (time-to-50% relengthening: IL-1β: 2071 ± 225 ms, P < 0.001 vs. vehicle, IL-1RA: 564 ± 247 ms, P < 0.001 vs. IL-1β), which was attenuated by an IL-1 receptor antagonist (IL-1RA). RT-DC analysis indicated that IL-1β reduced cardiomyocyte size (P < 0.001) and deformation (P < 0.05). RNA sequencing showed that genes involved in NF-κB signalling, autophagy and lysosomal protein degradation were enriched in hearts of septic WT but not in septic KO mice. Western blotting and qPCR disclosed that IL-1β activated NF-κB and its target genes, caused atrophy and decreased myosin protein in myocytes, which was accompanied by an increased autophagy gene expression. These effects were attenuated by IL-1RA. CONCLUSIONS IL-1β causes atrophy, impairs contractility and relaxation and decreases deformation of cardiomyocytes. Because NLRP3/IL-1β pathway inhibition attenuates cardiac atrophy and cardiomyopathy in sepsis, it could be useful to prevent septic cardiomyopathy.
Collapse
Affiliation(s)
- Katharina Busch
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Melanie Kny
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Nora Huang
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Department of Cardiology, Heart Center Brandenburg and Medical School Brandenburg (MHB), Bernau, Germany
| | - Tilman E Klassert
- ZIK Septomics, Host Septomics, Jena, Germany.,Jena University Hospital, Integrated Research and Treatment Center - Center for Sepsis Control and Care (CSCC), Jena, Germany
| | - Magdalena Stock
- ZIK Septomics, Host Septomics, Jena, Germany.,Jena University Hospital, Integrated Research and Treatment Center - Center for Sepsis Control and Care (CSCC), Jena, Germany
| | - Alexander Hahn
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Sebastian Graeger
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany
| | - Mihail Todiras
- Laboratory of Molecular Biology of Peptide Hormones, Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Nicolae Testemiţanu State University of Medicine and Pharmacy, Chișinău, Moldova
| | - Sibylle Schmidt
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Bishwas Chamling
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Department of Internal Medicine B, Molecular Cardiology, University Medicine Greifswald, Greifswald, Germany
| | - Michael Willenbrock
- Signal Transduction in Development and Cancer, Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Stefan Groß
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Department of Internal Medicine B, Molecular Cardiology, University Medicine Greifswald, Greifswald, Germany
| | - Doreen Biedenweg
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Centre for Innovation Competence - Humoral Immune Response in Cardiovascular Diseases, University of Greifswald, Greifswald, Germany
| | - Arnd Heuser
- Animal Phenotyping Facility, Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Claus Scheidereit
- Signal Transduction in Development and Cancer, Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Christian Butter
- Department of Cardiology, Heart Center Brandenburg and Medical School Brandenburg (MHB), Bernau, Germany
| | - Stephan B Felix
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Department of Internal Medicine B, Molecular Cardiology, University Medicine Greifswald, Greifswald, Germany
| | - Oliver Otto
- DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Centre for Innovation Competence - Humoral Immune Response in Cardiovascular Diseases, University of Greifswald, Greifswald, Germany
| | - Friedrich C Luft
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Hortense Slevogt
- ZIK Septomics, Host Septomics, Jena, Germany.,Jena University Hospital, Integrated Research and Treatment Center - Center for Sepsis Control and Care (CSCC), Jena, Germany
| | - Jens Fielitz
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin, Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany.,Department of Internal Medicine B, Molecular Cardiology, University Medicine Greifswald, Greifswald, Germany
| |
Collapse
|
12
|
Mahmoodzadeh S, Koch K, Schriever C, Xu J, Steinecker M, Leber J, Dworatzek E, Purfürst B, Kunz S, Recchia D, Canepari M, Heuser A, Di Francescantonio S, Morano I. Age-related decline in murine heart and skeletal muscle performance is attenuated by reduced Ahnak1 expression. J Cachexia Sarcopenia Muscle 2021; 12:1249-1265. [PMID: 34212535 PMCID: PMC8517348 DOI: 10.1002/jcsm.12749] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 05/13/2021] [Accepted: 06/08/2021] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Aging is associated with a progressive reduction in cellular function leading to poor health and loss of physical performance. Mitochondrial dysfunction is one of the hallmarks of aging; hence, interventions targeting mitochondrial dysfunction have the potential to provide preventive and therapeutic benefits to elderly individuals. Meta-analyses of age-related gene expression profiles showed that the expression of Ahnak1, a protein regulating several signal-transduction pathways including metabolic homeostasis, is increased with age, which is associated with low VO2MAX and poor muscle fitness. However, the role of Ahnak1 in the aging process remained unknown. Here, we investigated the age-related role of Ahnak1 in murine exercise capacity, mitochondrial function, and contractile function of cardiac and skeletal muscles. METHODS We employed 15- to 16-month-old female and male Ahnak1-knockout (Ahnak1-KO) and wild-type (WT) mice and performed morphometric, biochemical, and bioenergetics assays to evaluate the effects of Ahnak1 on exercise capacity and mitochondrial morphology and function in cardiomyocytes and tibialis anterior (TA) muscle. A human left ventricular (LV) cardiomyocyte cell line (AC16) was used to investigate the direct role of Ahnak1 in cardiomyocytes. RESULTS We found that the level of Ahnak1 protein is significantly up-regulated with age in the murine LV (1.9-fold) and TA (1.8-fold) tissues. The suppression of Ahnak1 was associated with improved exercise tolerance, as all aged adult Ahnak1-KO mice (100%) successfully completed the running programme, whereas approximately 31% male and 8% female WT mice could maintain the required running speed and distance. Transmission electron microscopic studies showed that LV and TA tissue specimens of aged adult Ahnak1-KO of both sexes have significantly more enlarged/elongated mitochondria and less small mitochondria compared with WT littermates (P < 0.01 and P < 0.001, respectively) at basal level. Further, we observed a shift in mitochondrial fission/fusion balance towards fusion in cardiomyocytes and TA muscle from aged adult Ahnak1-KO mice. The maximal and reserve respiratory capacities were significantly higher in cardiomyocytes from aged adult Ahnak1-KO mice compared with the WT counterparts (P < 0.05 and P < 0.01, respectively). Cardiomyocyte contractility and fatigue resistance of TA muscles were significantly increased in Ahnak1-KO mice of both sexes, compared with the WT groups. In vitro studies using AC16 cells have confirmed that the alteration of mitochondrial function is indeed a direct effect of Ahnak1. Finally, we presented Ahnak1 as a novel cardiac mitochondrial membrane-associated protein. CONCLUSIONS Our data suggest that Ahnak1 is involved in age-related cardiac and skeletal muscle dysfunction and could therefore serve as a promising therapeutical target.
Collapse
Affiliation(s)
- Shokoufeh Mahmoodzadeh
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Katharina Koch
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Cindy Schriever
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Jingman Xu
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,Heart Institute, School of Public Health, North China University of Science and Technology, Tangshan, China
| | - Maria Steinecker
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Joachim Leber
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Elke Dworatzek
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.,Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, and Berliner Institute of Health, Berlin, Germany
| | - Bettina Purfürst
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Severine Kunz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Deborah Recchia
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Monica Canepari
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Silvia Di Francescantonio
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,Experimental and Clinical Research Center, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Ingo Morano
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| |
Collapse
|
13
|
Kraeker K, Napieczynska H, Kedziora S, Haase N, Müller DN, Heuser A, Dechend R. Abstract P233: Microvascular Fingerprint Of Multi-Organ Imaging - New Insights In Preeclampsia Research. Hypertension 2021. [DOI: 10.1161/hyp.78.suppl_1.p233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
To establish the first protocol for high-resolution three-dimensional imaging of multiple organs in rodents, we performed microvasculature casting with Microfil silicone rubber substance in non-living rats and combined the method with advanced image analysis protocols after micro-CT scanning. This newly established method allows changes in individual organs to be visualized and examined in extraordinary detail as part of a multi-organ approach. Previously published protocols only address visualization of single organs or are insufficiently resolved with respect to vessel diameter analysis. With optimized staining protocols, samples can additionally be examined for possible structural changes such as inflammatory processes or fibrotic formation. Preeclampsia is a condition during pregnancy that leads to up to a 4-fold increased risk of maternal cardiovascular disease later in life, although symptoms usually resolve after delivery. In former preeclamptic rats, a reduction in microvascular density in the heart and brain with a simultaneous increase in retinal vessels has been described, even weeks after the disappearance of major features such as hypertension and albuminuria. The technique described will enhance studies of the vasculature in many other animal models and provide striking insights into vascular physiology necessary to drive translation.
Collapse
Affiliation(s)
- Kristin Kraeker
- Experimental and Clinical Rsch Cntr – a joint cooperation between the Max-Delbrück-Cntr for Molecular Medicine and the Charite – Universitaetsmedizin Berlin, Berlin, Germany
| | | | - Sarah Kedziora
- Experimental and Clinical Rsch Cntr – a joint cooperation between the Max-Delbrück-Cntr for Molecular Medicine and the Charite – Universitaetsmedizin Berlin, Berlin, Germany
| | - Nadine Haase
- Experimental and Clinical Rsch Cntr – a joint cooperation between the Max-Delbrück-Cntr for Molecular Medicine and the Charite – Universitaetsmedizin Berlin, Berlin, Germany
| | - Dominik N. Müller
- Experimental and Clinical Rsch Cntr – a joint cooperation between the Max-Delbrück-Cntr for Molecular Medicine and the Charite – Universitaetsmedizin Berlin, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück-Cntr for Molecular Medicine, Berlin, Germany
| | - Ralf Dechend
- Experimental and Clinical Rsch Cntr – a joint cooperation between the Max-Delbrück-Cntr for Molecular Medicine and the Charite – Universitaetsmedizin Berlin and Helios Clinic, Berlin, Germany
| |
Collapse
|
14
|
Haase N, Foster DJ, Cunningham MW, Bercher J, Nguyen T, Shulga-Morskaya S, Milstein S, Shaikh S, Rollins J, Golic M, Herse F, Kräker K, Bendix I, Serdar M, Napieczynska H, Heuser A, Gellhaus A, Thiele K, Wallukat G, Müller DN, LaMarca B, Dechend R. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. J Clin Invest 2021; 130:2928-2942. [PMID: 32338644 DOI: 10.1172/jci99417] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Accepted: 02/13/2020] [Indexed: 01/03/2023] Open
Affiliation(s)
- Nadine Haase
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | | | - Mark W Cunningham
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA
| | - Julia Bercher
- Experimental and Clinical Research Center, Berlin, Germany
| | - Tuyen Nguyen
- Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA
| | | | | | | | - Jeff Rollins
- Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA
| | - Michaela Golic
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Florian Herse
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Kristin Kräker
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Ivo Bendix
- Department of Pediatrics I Neonatology and Experimental Perinatal Neurosciences and
| | - Meray Serdar
- Department of Pediatrics I Neonatology and Experimental Perinatal Neurosciences and
| | - Hanna Napieczynska
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Alexandra Gellhaus
- Department of Gynecology and Obstetrics, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Kristin Thiele
- Department of Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Gerd Wallukat
- Experimental and Clinical Research Center, Berlin, Germany
| | - Dominik N Müller
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Babbette LaMarca
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.,Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, USA
| | - Ralf Dechend
- Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Berlin Germany.,Experimental and Clinical Research Center, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,HELIOS-Klinikum, Berlin, Germany.Preeclampsia, with the hallmark features of new-onset hypertension and proteinuria after 20 weeks of gestation, is a major cause of fetal and maternal morbidity and mortality. Studies have demonstrated a role for the renin-angiotensin system (RAS) in its pathogenesis; however, small-molecule RAS blockers are contraindicated because of fetal toxicity. We evaluated whether siRNA targeting maternal hepatic angiotensinogen (Agt, ) could ameliorate symptoms of preeclampsia without adverse placental or fetal effects in 2 rodent models. The first model used a cross of females expressing human Agt, with males expressing human renin, resulting in upregulation of the circulating and uteroplacental RAS. The second model induced ischemia/reperfusion injury and subsequent local and systemic inflammation by surgically reducing placental blood flow mid-gestation (reduced uterine perfusion pressure [RUPP]). These models featured hypertension, proteinuria, and fetal growth restriction, with altered biomarkers. siRNA treatment ameliorated the preeclamptic phenotype in both models, reduced blood pressure, and improved intrauterine growth restriction, with no observed deleterious effects on the fetus. Treatment also improved the angiogenic balance and proteinuria in the transgenic model, and it reduced angiotensin receptor activating antibodies in both. Thus, an RNAi therapeutic targeting Agt, ameliorated the clinical sequelae and improved fetal outcomes in 2 rodent models of preeclampsia
| |
Collapse
|
15
|
Ercu M, Markó L, Schächterle C, Tsvetkov D, Cui Y, Maghsodi S, Bartolomaeus TU, Maass PG, Zühlke K, Gregersen N, Hübner N, Hodge R, Mühl A, Pohl B, Illas RM, Geelhaar A, Walter S, Napieczynska H, Schelenz S, Taube M, Heuser A, Anistan YM, Qadri F, Todiras M, Plehm R, Popova E, Langanki R, Eichhorst J, Lehmann M, Wiesner B, Russwurm M, Forslund SK, Kamer I, Müller DN, Gollasch M, Aydin A, Bähring S, Bader M, Luft FC, Klussmann E. Phosphodiesterase 3A and Arterial Hypertension. Circulation 2020; 142:133-149. [DOI: 10.1161/circulationaha.119.043061] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
High blood pressure is the primary risk factor for cardiovascular death worldwide. Autosomal dominant hypertension with brachydactyly clinically resembles salt-resistant essential hypertension and causes death by stroke before 50 years of age. We recently implicated the gene encoding phosphodiesterase 3A (
PDE3A
); however, in vivo modeling of the genetic defect and thus showing an involvement of mutant PDE3A is lacking.
Methods:
We used genetic mapping, sequencing, transgenic technology, CRISPR-Cas9 gene editing, immunoblotting, and fluorescence resonance energy transfer. We identified new patients, performed extensive animal phenotyping, and explored new signaling pathways.
Results:
We describe a novel mutation within a 15 base pair (bp) region of the
PDE3A
gene and define this segment as a mutational hotspot in hypertension with brachydactyly. The mutations cause an increase in enzyme activity. A CRISPR/Cas9-generated rat model, with a 9-bp deletion within the hotspot analogous to a human deletion, recapitulates hypertension with brachydactyly. In mice, mutant transgenic PDE3A overexpression in smooth muscle cells confirmed that mutant PDE3A causes hypertension. The mutant PDE3A enzymes display consistent changes in their phosphorylation and an increased interaction with the 14-3-3θ adaptor protein. This aberrant signaling is associated with an increase in vascular smooth muscle cell proliferation and changes in vessel morphology and function.
Conclusions:
The mutated
PDE3A
gene drives mechanisms that increase peripheral vascular resistance causing hypertension. We present 2 new animal models that will serve to elucidate the underlying mechanisms further. Our findings could facilitate the search for new antihypertensive treatments.
Collapse
Affiliation(s)
- Maria Ercu
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
| | - Lajos Markó
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, Germany (L.M., T.U.P.B., N.H., Y.-M.A., S.K.F.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Carolin Schächterle
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Dmitry Tsvetkov
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Yingqiu Cui
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Sara Maghsodi
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Theda U.P. Bartolomaeus
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, Germany (L.M., T.U.P.B., N.H., Y.-M.A., S.K.F.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Philipp G. Maass
- Genetics and Genome Biology Program, Sickkids Research Institute and Department of Molecular Genetics, University of Toronto, ON, Canada (P.G.M.)
| | - Kerstin Zühlke
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Nerine Gregersen
- Auckland District Health Board (ADHB), Genetic Health Service New Zealand – Northern Hub (N.G.)
| | - Norbert Hübner
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, Germany (L.M., T.U.P.B., N.H., Y.-M.A., S.K.F.)
| | - Russell Hodge
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Astrid Mühl
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Bärbel Pohl
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Rosana Molé Illas
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Andrea Geelhaar
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Stephan Walter
- Abteilung für Nephrologie/Hypertensiologie, St. Vincenz Krankenhaus, Limburg, Germany (S.W.)
| | - Hanna Napieczynska
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Stefanie Schelenz
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Martin Taube
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Yoland-Marie Anistan
- Charité-Universitätsmedizin Berlin, Germany (L.M., T.U.P.B., N.H., Y.-M.A., S.K.F.)
- Division of Nephrology and Intensive Care Medicine, Medical Department, Charité-Universitätsmedizin, Berlin, Germany (Y.-M.A., M.G.)
| | - Fatimunnisa Qadri
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Mihail Todiras
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Ralph Plehm
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Elena Popova
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Reika Langanki
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Jenny Eichhorst
- Leibniz-Forschingsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L., B.W.)
| | - Martin Lehmann
- Leibniz-Forschingsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L., B.W.)
| | - Burkhard Wiesner
- Leibniz-Forschingsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany (J.E., M.L., B.W.)
| | - Michael Russwurm
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät MA N1, Ruhr-Universität Bochum, Germany (M.R.)
| | - Sofia K. Forslund
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Charité-Universitätsmedizin Berlin, Germany (L.M., T.U.P.B., N.H., Y.-M.A., S.K.F.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
- Berlin Institute of Health (BIH), Germany (S.K.F.)
| | - Ilona Kamer
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Dominik N. Müller
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Maik Gollasch
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
- Division of Nephrology and Intensive Care Medicine, Medical Department, Charité-Universitätsmedizin, Berlin, Germany (Y.-M.A., M.G.)
- Department of Internal Medicine and Geriatrics, University Medicine Greifswald, Germany (M.G.)
| | - Atakan Aydin
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
| | - Sylvia Bähring
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
- Institute for Biology, University of Lübeck, Germany (M.B.)
| | - Friedrich C. Luft
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., C.S., D.T., Y.C., T.U.P.B., R.M.I., S.K.F., I.K., D.N.M., M.G., S.B., F.C.L.)
| | - Enno Klussmann
- Max-Delbrück-Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany (M.E., C.S., S.M., K.Z., N.H., R.H., A.M., B.P., A.G., H.N., S.S., M. Taube, A.H., F.Q., M. Todiras, R.P., E.P., R.L., S.K.F., D.N.M., A.A., M.B., F.C.L., E.K.)
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (M.E., L.M., C.S., T.U.P.B., N.H., S.K.F., D.N.M., M.B., E.K.)
| |
Collapse
|
16
|
Bockstahler M, Fischer A, Goetzke CC, Neumaier HL, Sauter M, Kespohl M, Müller AM, Meckes C, Salbach C, Schenk M, Heuser A, Landmesser U, Weiner J, Meder B, Lehmann L, Kratzer A, Klingel K, Katus HA, Kaya Z, Beling A. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. Circulation 2020; 141:1885-1902. [DOI: 10.1161/circulationaha.119.043171] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Background:
Immune checkpoint inhibitor (ICI) therapy is often accompanied by immune-related pathology, with an increasing occurrence of high-risk ICI-related myocarditis. Understanding the mechanisms involved in this side effect could enable the development of management strategies. In mouse models, immune checkpoints, such as PD-1 (programmed cell death protein 1), control the threshold of self-antigen responses directed against cardiac TnI (troponin I). We aimed to identify how the immunoproteasome, the main proteolytic machinery in immune cells harboring 3 distinct protease activities in the LMP2 (low-molecular-weight protein 2), LMP7 (low-molecular-weight protein 7), and MECL1 (multicatalytic endopeptidase complex subunit 1) subunit, affects TnI-directed autoimmune pathology of the heart.
Methods:
TnI-directed autoimmune myocarditis (TnI-AM), a CD4
+
T-cell–mediated disease, was induced in mice lacking all 3 immunoproteasome subunits (triple-ip
−/−
) or lacking either the gene encoding LMP2 and LMP7 by immunization with a cardiac TnI peptide. Alternatively, before induction of TnI-AM or after establishment of autoimmune myocarditis, mice were treated with the immunoproteasome inhibitor ONX 0914. Immune parameters defining heart-specific autoimmunity were investigated in experimental TnI-AM and in 2 cases of ICI-related myocarditis.
Results:
All immunoproteasome-deficient strains showed mitigated autoimmune-related cardiac pathology with less inflammation, lower proinflammatory and chemotactic cytokines, less interleukin-17 production, and reduced fibrosis formation. Protection from TnI-directed autoimmune heart pathology with improved cardiac function in LMP7
−/−
mice involved a changed balance between effector and regulatory CD4
+
T cells in the spleen, with CD4
+
T cells from LMP7
−
/−
mice showing a higher expression of inhibitory PD-1 molecules. Blocked immunoproteasome proteolysis, by treatment of TLR2 (Toll-like receptor 2)–engaged and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)–engaged CD14
+
monocytes with ONX 0914, diminished proinflammatory cytokine responses, thereby reducing the boost for the expansion of self-reactive CD4
+
T cells. Correspondingly, in mice, ONX 0914 treatment reversed cardiac autoimmune pathology, preventing the induction and progression of TnI-AM when self-reactive CD4
+
T cells were primed. The autoimmune signature during experimental TnI-AM, with high immunoproteasome expression, immunoglobulin G deposition, interleukin-17 production in heart tissue, and TnI-directed humoral autoimmune responses, was also present in 2 cases of ICI-related myocarditis, demonstrating the activation of heart-specific autoimmune reactions by ICI therapy.
Conclusions:
By reversing heart-specific autoimmune responses, immunoproteasome inhibitors applied to a mouse model demonstrate their potential to aid in the management of autoimmune myocarditis in humans, possibly including patients with ICI-related heart-specific autoimmunity.
Collapse
Affiliation(s)
- Mariella Bockstahler
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
| | - Andrea Fischer
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
| | - Carl Christoph Goetzke
- Institute of Biochemistry (C.C.G., H.L.N., M.K., A.B.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Germany (C.C.G., M.K., U.L., A.K., A.B.)
| | - Hannah Louise Neumaier
- Institute of Biochemistry (C.C.G., H.L.N., M.K., A.B.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
| | - Martina Sauter
- Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Germany (M.S., K.K.)
| | - Meike Kespohl
- Institute of Biochemistry (C.C.G., H.L.N., M.K., A.B.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Germany (C.C.G., M.K., U.L., A.K., A.B.)
| | - Anna-Maria Müller
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
| | - Christin Meckes
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
| | - Christian Salbach
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
| | - Mirjam Schenk
- Institute of Pathology, University of Bern, Switzerland (M.S.)
| | - Arnd Heuser
- Core Unit Pathophysiology (A.H.), Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - Ulf Landmesser
- Medizinische Klinik für Kardiologie Campus Benjamin Franklin (U.L., A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Germany (C.C.G., M.K., U.L., A.K., A.B.)
| | - January Weiner
- Core Unit Bioinformatics (J.W.), Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - Benjamin Meder
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg/Mannheim, Heidelberg, Germany (B.M., L.L., H.A.K., Z.K.)
| | - Lorenz Lehmann
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg/Mannheim, Heidelberg, Germany (B.M., L.L., H.A.K., Z.K.)
- Cardio-Oncology Unit, University Hospital of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany (L.L.)
| | - Adelheid Kratzer
- Medizinische Klinik für Kardiologie Campus Benjamin Franklin (U.L., A.K.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Germany (C.C.G., M.K., U.L., A.K., A.B.)
| | - Karin Klingel
- Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Germany (M.S., K.K.)
| | - Hugo A. Katus
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg/Mannheim, Heidelberg, Germany (B.M., L.L., H.A.K., Z.K.)
| | - Ziya Kaya
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany (M.B., A.F., A.-M.M., C.M., C.S., B.M., L.L., H.A.K., Z.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg/Mannheim, Heidelberg, Germany (B.M., L.L., H.A.K., Z.K.)
| | - Antje Beling
- Institute of Biochemistry (C.C.G., H.L.N., M.K., A.B.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Germany (C.C.G., M.K., U.L., A.K., A.B.)
| |
Collapse
|
17
|
Neumaier HL, Harel S, Klingel K, Kaya Z, Heuser A, Kespohl M, Beling A. ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage. Cells 2020; 9:cells9051093. [PMID: 32354159 PMCID: PMC7290815 DOI: 10.3390/cells9051093] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 04/21/2020] [Accepted: 04/23/2020] [Indexed: 12/16/2022] Open
Abstract
: Inhibition of proteasome function by small molecules is highly efficacious in cancer treatment. Other than non-selective proteasome inhibitors, immunoproteasome-specific inhibitors allow for specific targeting of the proteasome in immune cells and the profound anti-inflammatory potential of such compounds revealed implications for inflammatory scenarios. For pathogen-triggered inflammation, however, the efficacy of immunoproteasome inhibitors is controversial. In this study, we investigated how ONX 0914, an immunoproteasome-selective inhibitor, influences CoxsackievirusB3 infection in NMRI mice, resulting in the development of acute and chronic myocarditis, which is accompanied by formation of the immunoproteasome in heart tissue. In groups in which ONX 0914 treatment was initiated once viral cytotoxicity had emerged in the heart, ONX 0914 had no anti-inflammatory effect in the acute or chronic stages. ONX 0914 treatment initiated prior to infection, however, increased viral cytotoxicity in cardiomyocytes, promoting infiltration of myeloid immune cells into the heart. At this stage, ONX 0914 completely inhibited the β5 subunit of the standard cardiac proteasome and less efficiently blocked its immunoproteasome counterpart LMP7. In conclusion, ONX 0914 unselectively perturbs cardiac proteasome function in viral myocarditis of NMRI mice, reduces the capacity of the host to control the viral burden and promotes cardiac inflammation.
Collapse
Affiliation(s)
- Hannah Louise Neumaier
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, 10117 Berlin, Germany; (H.L.N.); (S.H.); (M.K.)
| | - Shelly Harel
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, 10117 Berlin, Germany; (H.L.N.); (S.H.); (M.K.)
| | - Karin Klingel
- Institute for Cardiopathology, University of Tuebingen, 72074 Tuebingen, Germany;
| | - Ziya Kaya
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany;
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg/Mannheim, 69120 Heidelberg, Germany
| | - Arnd Heuser
- Max-Delbrueck-Center for Molecular Medicine, 10115 Berlin, Germany;
| | - Meike Kespohl
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, 10117 Berlin, Germany; (H.L.N.); (S.H.); (M.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, 10785 Berlin, Germany
| | - Antje Beling
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, 10117 Berlin, Germany; (H.L.N.); (S.H.); (M.K.)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, 10785 Berlin, Germany
- Correspondence:
| |
Collapse
|
18
|
Kräker K, O'Driscoll JM, Schütte T, Herse F, Patey O, Golic M, Geisberger S, Verlohren S, Birukov A, Heuser A, Müller DN, Thilaganathan B, Dechend R, Haase N. Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia. Hypertension 2019; 75:202-210. [PMID: 31786987 DOI: 10.1161/hypertensionaha.119.13219] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Preeclampsia is associated with increased cardiovascular long-term risk; however, the underlying functional and structural mechanisms are unknown. We investigated maternal cardiac alterations after preeclampsia. Female rats harboring the human angiotensinogen gene [TGR(hAogen)L1623] develop a preeclamptic phenotype with hypertension and albuminuria during pregnancy when mated with male rats bearing the human renin gene [TGR(hRen)L10J] but behave physiologically normal before and after pregnancy. Furthermore, rats were treated with pravastatin. We tested the hypothesis that statins are a potential therapeutic intervention to reduce cardiovascular alterations due to simulated preeclamptic pregnancy. Although hypertension persists for only 8 days in pregnancy, former preeclampsia rats exhibit significant cardiac hypertrophy 28 days after pregnancy observed in both speckle tracking echocardiography and histological staining. In addition, fibrosis and capillary rarefaction was evident. Pravastatin treatment ameliorated the remodeling and improved cardiac output postpartum. Preeclamptic pregnancy induces irreversible structural changes of cardiac hypertrophy and fibrosis, which can be moderated by pravastatin treatment. This pathological cardiac remodeling might be involved in increased cardiovascular risk in later life.
Collapse
Affiliation(s)
- Kristin Kräker
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Jamie M O'Driscoll
- Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (J.M.O., O.P., B.T.).,Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, United Kingdom (J.M.O., O.P., B.T.).,Canterbury Christ Church University, School of Human and Life Sciences, Kent, United Kingdom (J.M.O.)
| | - Till Schütte
- Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Institute of Pharmacology (T.S.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | - Florian Herse
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Olga Patey
- Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (J.M.O., O.P., B.T.).,Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, United Kingdom (J.M.O., O.P., B.T.)
| | - Michaela Golic
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Sabrina Geisberger
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Stefan Verlohren
- Institute of Obstetrics (S.V.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | - Anna Birukov
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Arnd Heuser
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Dominik N Müller
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| | - Basky Thilaganathan
- Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (J.M.O., O.P., B.T.).,Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, United Kingdom (J.M.O., O.P., B.T.)
| | - Ralf Dechend
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,HELIOS-Klinikum, Berlin, Germany (R.D.)
| | - Nadine Haase
- From the Experimental and Clinical Research Center-a joint cooperation between the Max Delbrück Center for Molecular Medicine and the Charité-Universitätsmedizin Berlin, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Berlin Institute of Health, Germany (K.K., T.S., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,German Centre for Cardiovascular Research, partner site Berlin, Germany (K.K., T.S., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany (K.K., F.H., M.G., S.G., A.B., D.N.M., R.D., N.H.).,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (K.K., F.H., M.G., S.G., A.B., A.H., D.N.M., N.H.)
| |
Collapse
|
19
|
Eisenhauer A, Müller M, Heuser A, Kolevica A, Glüer CC, Both M, Laue C, Hehn UV, Kloth S, Shroff R, Schrezenmeir J. Calcium isotope ratios in blood and urine: A new biomarker for the diagnosis of osteoporosis. Bone Rep 2019; 10:100200. [PMID: 30997369 PMCID: PMC6453776 DOI: 10.1016/j.bonr.2019.100200] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 03/10/2019] [Indexed: 11/30/2022] Open
Abstract
We assessed the potential of Calcium (Ca) isotope fractionation measurements in blood (δ44/42CaBlood) and urine (δ44/42CaUrine) as a new biomarker for the diagnosis of osteoporosis. One hundred post-menopausal women aged 50 to 75 years underwent dual-energy X-ray absorptiometry (DXA), the gold standard for determination of bone mineral density. After exclusion of women with kidney failure and vitamin D deficiency (<25 nmol/l) 80 women remained in the study. Of these women 14 fulfilled the standard diagnostic criteria for osteoporosis based on DXA. Both the δ44/42CaBlood (p < 0.001) and δ44/42CaUrine (p = 0.004) values were significantly different in women with osteoporosis (δ44/42CaBlood: −0.99 ± 0.10‰, δ 44/42CaUrine: +0.10 ± 0.21‰, (Mean ± one standard deviation (SD), n = 14)) from those without osteoporosis (δ44/42CaBlood: −0.84 ± 0.14‰, δ44/42CaUrine: +0.35 ± 0.33‰, (SD), n = 66). This corresponded to the average Ca concentrations in morning spot urine samples ([Ca]Urine) which were higher (p = 0.041) in those women suffering from osteoporosis ([Ca]Urine-Osteoporosis: 2.58 ± 1.26 mmol/l, (SD), n = 14) than in the control group ([Ca]Urine-Control: 1.96 ± 1.39 mmol/l, (SD), n = 66). However, blood Ca concentrations ([Ca]Blood) were statistically indistinguishable between groups ([Ca]Blood, control: 2.39 ± 0.10 mmol/l (SD), n = 66); osteoporosis group: 2.43 ± 0.10 mmol/l (SD, n = 14) and were also not correlated to their corresponding Ca isotope compositions. The δ44/42CaBlood and δ44/42CaUrine values correlated significantly (p = 0.004 to p = 0.031) with their corresponding DXA data indicating that both Ca isotope ratios are biomarkers for osteoporosis. Furthermore, Ca isotope ratios were significantly correlated to other clinical parameters ([Ca]Urine, ([Ca]Urine/Creatinine)) and biomarkers (CRP, CTX/P1NP) associated with bone mineralization and demineralization. From regression analysis it can be shown that the δ44/42CaBlood values are the best biomarker for osteoporosis and that no other clinical parameters need to be taken into account in order to improve diagnosis. Cut-off values for discrimination of subjects suffering from osteoporosis were − 0.85‰ and 0.16‰ for δ44/42CaBlood and δ44/42CaUrine, respectively. Corresponding sensitivities were 100% for δ44/42CaBlood and ~79% for δ44/42CaUrine. Apparent specificities were ~55% for δ44/42CaBlood and ~71%. The apparent discrepancy in the number of diagnosed cases is reconciled by the different methodological approaches to diagnose osteoporosis. DXA reflects the bone mass density (BMD) of selected bones only (femur and spine) whereas the Ca isotope biomarker reflects bone Ca loss of the whole skeleton. In addition, the close correlation between Ca isotopes and biomarkers of bone demineralization suggest that early changes in bone demineralization are detected by Ca isotope values, long before radiological changes in BMD can manifest on DXA. Further studies are required to independently confirm that Ca isotope measurement provide a sensitive, non-invasive and radiation-free method for the diagnosis of osteoporosis.
Collapse
Affiliation(s)
- A Eisenhauer
- GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany.,OSTEOLABS GmbH, c/o GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany
| | - M Müller
- University Medical Center Schleswig-Holstein (UKSH), Arnold-Heller-Str. 3, 24105 Kiel, Germany.,OSTEOLABS GmbH, c/o GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany
| | - A Heuser
- GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany.,OSTEOLABS GmbH, c/o GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany
| | - A Kolevica
- GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany.,OSTEOLABS GmbH, c/o GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany
| | - C-C Glüer
- Sektion Biomedizinische Bildgebung, Klinik für Radiologie und Neuroradiologie, Am Botanischen Garten 14, 24118 Kiel, Germany
| | - M Both
- Klinik für Neuroradiologie und Radiologie, (UKSH), Arnold-Heller-Str. 3, 24105 Kiel, Germany
| | - C Laue
- Clinical Research Center Kiel GmbH, Schauenburgerstraße 116, 24118 Kiel, Germany
| | - U V Hehn
- Medistat, GmbH, Kieler Straße 15, 24119 Kronshagen, Germany
| | - S Kloth
- OSTEOLABS GmbH, c/o GEOMAR Helmholtz Centre for Ocean Research Kiel, 24148 Kiel, Wischhofstr.1-3, Germany
| | - R Shroff
- Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, United Kingdom of Great Britain and Northern Ireland
| | - J Schrezenmeir
- Clinical Research Center Kiel GmbH, Schauenburgerstraße 116, 24118 Kiel, Germany
| |
Collapse
|
20
|
Barros CC, Schadock I, Sihn G, Rother F, Xu P, Popova E, Lapidus I, Plehm R, Heuser A, Todiras M, Bachmann S, Alenina N, Araujo RC, Pesquero JB, Bader M. Chronic Overexpression of Bradykinin in Kidney Causes Polyuria and Cardiac Hypertrophy. Front Med (Lausanne) 2018; 5:338. [PMID: 30560131 PMCID: PMC6287039 DOI: 10.3389/fmed.2018.00338] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2018] [Accepted: 11/16/2018] [Indexed: 01/06/2023] Open
Abstract
Acute intra-renal infusion of bradykinin increases diuresis and natriuresis via inhibition of vasopressin activity. However, the consequences of chronically increased bradykinin in the kidneys have not yet been studied. A new transgenic animal model producing an excess of bradykinin by proximal tubular cells (KapBK rats) was generated and submitted to different salt containing diets to analyze changes in blood pressure and other cardiovascular parameters, urine excretion, and composition, as well as levels and expression of renin-angiotensin system components. Despite that KapBK rats excrete more urine and sodium, they have similar blood pressure as controls with the exception of a small increase in systolic blood pressure (SBP). However, they present decreased renal artery blood flow, increased intrarenal expression of angiotensinogen, and decreased mRNA expression of vasopressin V1A receptor (AVPR1A), suggesting a mechanism for the previously described reduction of renal vasopressin sensitivity by bradykinin. Additionally, reduced heart rate variability (HRV), increased cardiac output and frequency, and the development of cardiac hypertrophy are the main chronic effects observed in the cardiovascular system. In conclusion: (1) the transgenic KapBK rat is a useful model for studying chronic effects of bradykinin in kidney; (2) increased renal bradykinin causes changes in renin angiotensin system regulation; (3) decreased renal vasopressin sensitivity in KapBK rats is related to decreased V1A receptor expression; (4) although increased renal levels of bradykinin causes no changes in mean arterial pressure (MAP), it causes reduction in HRV, augmentation in cardiac frequency and output and consequently cardiac hypertrophy in rats after 6 months of age.
Collapse
Affiliation(s)
- Carlos C Barros
- Department of Nutrition, Federal University of Pelotas, Pelotas, Brazil
| | - Ines Schadock
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil.,Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Gabin Sihn
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | | | - Ping Xu
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Elena Popova
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Irina Lapidus
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Ralph Plehm
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Arnd Heuser
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Mihail Todiras
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | | | - Natalia Alenina
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - Ronaldo C Araujo
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil
| | - Joao B Pesquero
- Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil
| | - Michael Bader
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Charite-University Medicine, Berlin, Germany.,Federal University of Minas Gerais, Belo Horizonte, Brazil.,Berlin Institute of Health (BIH), Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.,Institute for Biology, University of Lübeck, Lübeck, Germany
| |
Collapse
|
21
|
Gross A, Pack LAP, Schacht GM, Kant S, Ungewiss H, Meir M, Schlegel N, Preisinger C, Boor P, Guldiken N, Krusche CA, Sellge G, Trautwein C, Waschke J, Heuser A, Leube RE, Strnad P. Desmoglein 2, but not desmocollin 2, protects intestinal epithelia from injury. Mucosal Immunol 2018; 11:1630-1639. [PMID: 30115995 DOI: 10.1038/s41385-018-0062-z] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 06/14/2018] [Accepted: 06/26/2018] [Indexed: 02/04/2023]
Abstract
Desmosomes are the least understood intercellular junctions in the intestinal epithelia and provide cell-cell adhesion via the cadherins desmoglein (Dsg)2 and desmocollin (Dsc)2. We studied these cadherins in Crohn's disease (CD) patients and in newly generated conditional villin-Cre DSG2 and DSC2 knockout mice (DSG2ΔIEC; DSC2ΔIEC). CD patients exhibited altered desmosomes and reduced Dsg2/Dsc2 levels. The intestines of both transgenic animal lines were histopathologically inconspicuous. However, DSG2ΔIEC, but not DSC2ΔIEC mice displayed an increased intestinal permeability, a wider desmosomal space as well as alterations in desmosomal and tight junction components. After dextran sodium sulfate (DSS) treatment and Citrobacter rodentium exposure, DSG2ΔIEC mice developed a more-pronounced colitis, an enhanced intestinal epithelial barrier disruption, leading to a stronger inflammation and activation of epithelial pSTAT3 signaling. No susceptibility to DSS-induced intestinal injury was noted in DSC2ΔIEC animals. Dsg2 interacted with the cytoprotective chaperone Hsp70. Accordingly, DSG2ΔIEC mice had lower Hsp70 levels in the plasma membrane compartment, whereas DSC2ΔIEC mice displayed a compensatory recruitment of galectin 3, a junction-tightening protein. Our results demonstrate that Dsg2, but not Dsc2 is required for the integrity of the intestinal epithelial barrier in vivo.
Collapse
Affiliation(s)
- Annika Gross
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Lotta A P Pack
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Gabriel M Schacht
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Sebastian Kant
- Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany
| | - Hanna Ungewiss
- Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Michael Meir
- Department of Surgery I, University of Würzburg, Würzburg, Germany
| | - Nicolas Schlegel
- Department of Surgery I, University of Würzburg, Würzburg, Germany
| | | | - Peter Boor
- Institute of Pathology and Department of Nephrology, University Hospital Aachen, Aachen, Germany
| | - Nurdan Guldiken
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Claudia A Krusche
- Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany
| | - Gernot Sellge
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Christian Trautwein
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany
| | - Jens Waschke
- Department of Surgery I, University of Würzburg, Würzburg, Germany
| | - Arnd Heuser
- Max-Delbrück-Center of Molecular Medicine, Berlin, Germany
| | - Rudolf E Leube
- Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany
| | - Pavel Strnad
- Department of Medicine III and IZKF, University Hospital Aachen, Aachen, Germany.
| |
Collapse
|
22
|
Meyer IS, Goetzke CC, Kespohl M, Sauter M, Heuser A, Eckstein V, Vornlocher HP, Anderson DG, Haas J, Meder B, Katus HA, Klingel K, Beling A, Leuschner F. Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis. Front Immunol 2018; 9:2303. [PMID: 30349538 PMCID: PMC6186826 DOI: 10.3389/fimmu.2018.02303] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Accepted: 09/17/2018] [Indexed: 12/11/2022] Open
Abstract
Myocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-inflammatory and pro-fibrotic cytokine production follows. In patients, the overall inflammatory burden determines the disease outcome. Following the aim to define specific molecules that drive both immunopathology and/or autoimmunity in inflammatory heart disease, here we report on increased expression of colony stimulating factor 1 (CSF-1) in patients with myocarditis. CSF-1 controls monocytes originating from hematopoietic stem cells and subsequent progenitor stages. Both, monocytes and macrophages are centrally involved in mediating tissue damage and fibrotic scarring in the heart. CSF-1 influences monocytes via engagement of CSF-1 receptor, and it is also produced by cells of the mononuclear phagocyte system themselves. Based on this, we sought to modulate the virus-triggered inflammatory response in an experimental model of Coxsackievirus B3-induced myocarditis by silencing the CSF-1 axis in myeloid cells using nanoparticle-encapsulated siRNA. siCSF-1 inverted virus-mediated immunopathology as reflected by lower troponin T levels, a reduction of accumulating myeloid cells in heart tissue and improved cardiac function. Importantly, pathogen control was maintained and the virus was efficiently cleared from heart tissue. Since viral heart disease triggers heart-directed autoimmunity, in a second approach we investigated the influence of CSF-1 upon manifestation of heart tissue inflammation during experimental autoimmune myocarditis (EAM). EAM was induced in Balb/c mice by immunization with a myocarditogenic myosin-heavy chain-derived peptide dissolved in complete Freund's adjuvant. siCSF-1 treatment initiated upon established disease inhibited monocyte infiltration into heart tissue and this suppressed cardiac injury as reflected by diminished cardiac fibrosis and improved cardiac function at later states. Mechanistically, we found that suppression of CSF-1 production arrested both differentiation and maturation of monocytes and their precursors in the bone marrow. In conclusion, during viral and autoimmune myocarditis silencing of the myeloid CSF-1 axis by nanoparticle-encapsulated siRNA is beneficial for preventing inflammatory tissue damage in the heart and preserving cardiac function without compromising innate immunity's critical defense mechanisms.
Collapse
Affiliation(s)
- Ingmar Sören Meyer
- Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Heidelberg, Germany
| | - Carl Christoph Goetzke
- Institute of Biochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - Meike Kespohl
- Institute of Biochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - Martina Sauter
- Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany
| | - Arnd Heuser
- Max-Delbrueck-Center for Molecular Medicine Berlin, Berlin, Germany
| | - Volker Eckstein
- Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | | | - Daniel G Anderson
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.,Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.,Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, United States
| | - Jan Haas
- Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Heidelberg, Germany
| | - Benjamin Meder
- Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Heidelberg, Germany
| | - Hugo Albert Katus
- Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Heidelberg, Germany
| | - Karin Klingel
- Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany
| | - Antje Beling
- Institute of Biochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - Florian Leuschner
- Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg-Mannheim, Heidelberg, Germany
| |
Collapse
|
23
|
Kräker K, Herse F, Verlohren S, Golic M, Heuser A, Richter M, Birukov A, Sporbert A, O’Driscoll JM, Thilaganathan B, Müller DN, Dechend R, Haase N. 54. Cardiac small vessel imaging by light sheet microscopy and micro CT – discovering the missing link between preeclampsia and higher risk for further cardiovascular disease. Pregnancy Hypertens 2018. [DOI: 10.1016/j.preghy.2018.08.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
24
|
Kraeker K, Haase N, Herse F, Verlohren S, Heuser A, Sporbert A, Richter M, O'Driscoll J, Thilaganathan B, Mueller DN, Dechend R. Abstract P180: Cardiac Small Vessel Imaging by Light Sheet Microscopy and Micro CT - Discovering the Missing Link Between Preeclampsia and Higher Risk for Further Cardiovascular Disease. Hypertension 2018. [DOI: 10.1161/hyp.72.suppl_1.p180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
In preeclampsia, symptoms like high blood pressure and albuminuria are caused by a state of anti-angiogenic and immune imbalance resulting in endothelial dysfunction. The evaluation of smaller vessels is a challenge, but clinically of increasing importance.
Objective:
We want to examine whether the increased risk for postpartum maternal cardiovascular disease after preeclamptic pregnancy is resultant from microvascular changes in connection with the structural remodelling processes.
Methods:
We compared echo data from a human cohort with data from our transgenic animal model (hAGTxhRen) after preeclamptic pregnancy. In addition, we investigated cardiac changes in gene (qPCR) and protein expression levels (ELISA, IHC staining) in maternal rats, as well as alterations in microvascular 3D remodeling using LSFM and Micro CT.
Results:
We were able to show that the echo changes in our transgenic rat model are comparable to human data. Basic parameters like ejection fraction (human 0,91; animal 0,86), end-systolic volume (human 1,26; animal 1,22) or heart rate (human 1,13; animal 1,16) are altered at the end of pregnancy in same direction. Also markers of hypertrophy like relative wall thickness (human 1,19; animal 1,21) are changed. With the help of speckle trackle analysis, a more sensitive method to detect subclinical changes in hearts functionality, both groups show a reduction of global longitudinal strain (human 0,75; animal 0,6) and strain rate (human 0,81; animal 0,73). The microvasculature and entire vascular network has been visualized so far only in cleared mouse brains and partially in adult mouse hearts. Here, we present the 3D network of lectin-labeled blood vessels in cleared adult rat hearts with the analysis of cardiac small vessels with regard to branching points, vessel length and up to a diameter of 6μm.
Discussion:
Preeclampsia leads to a weakened functionality in postpartum hearts, in a human cohort as well as in our transgenic animal model. Studies are underway to quantify coronary microvascular pathology as a possible missing link between preeclampsia and higher risk for further cardiovascular disease. (values show postpartum change compared to non-pregnant)
Collapse
Affiliation(s)
- Kristin Kraeker
- Experimental and Clinical Rsch Cntr; Max-Delbrück-Cntr for Molecular Medicine; Berlin Institute of Health; German Cntr for Cardiovascular Rsch, Berlin, Germany
| | - Nadine Haase
- Experimental and Clinical Rsch Cntr; Max-Delbrück-Cntr for Molecular Medicine; Berlin Institute of Health; German Cntr for Cardiovascular Rsch, Berlin, Germany
| | - Florian Herse
- Experimental and Clinical Rsch Cntr; Max-Delbrück-Cntr for Molecular Medicine; Charité – Universitätsmedizin Berlin; Berlin Institute of Health, Berlin, Germany
| | | | - Arnd Heuser
- Max-Delbrueck-Cntr for Molecular Medicine, Berlin, Germany
| | - Anje Sporbert
- Max-Delbrueck-Cntr for Molecular Medicine, Berlin, Germany
| | | | | | | | - Dominik N. Mueller
- Experimental and Clinical Rsch Cntr; Max-Delbrück-Cntr for Molecular Medicine; Charité - Universitätsmedizin; Berlin Institute of Health; German Cntr for Cardiovascular Rsch, Berlin, Germany
| | - Ralf Dechend
- Experimental and Clinical Rsch Cntr; Charité – Universitätsmedizin Berlin; Berlin Institute of Health; Helios Klinikum, Berlin, Germany
| |
Collapse
|
25
|
Bégay V, Baumeier C, Zimmermann K, Heuser A, Leutz A. The C/EBPβ LIP isoform rescues loss of C/EBPβ function in the mouse. Sci Rep 2018; 8:8417. [PMID: 29849099 PMCID: PMC5976626 DOI: 10.1038/s41598-018-26579-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 03/22/2018] [Indexed: 12/26/2022] Open
Abstract
The transcription factor C/EBPβ regulates hematopoiesis, bone, liver, fat, and skin homeostasis, and female reproduction. C/EBPβ protein expression from its single transcript occurs by alternative in-frame translation initiation at consecutive start sites to generate three isoforms, two long (LAP*, LAP) and one truncated (LIP), with the same C-terminal bZip dimerization domain. The long C/EBPβ isoforms are considered gene activators, whereas the LIP isoform reportedly acts as a dominant-negative repressor. Here, we tested the putative repressor functions of the C/EBPβ LIP isoform in mice by comparing monoallelic WT or LIP knockin mice with Cebpb knockout mice, in combination with monoallelic Cebpa mice. The C/EBPβ LIP isoform was sufficient to function in coordination with C/EBPα in murine development, adipose tissue and sebocyte differentiation, and female fertility. Thus, the C/EBPβ LIP isoform likely has more physiological functions than its currently known role as a dominant-negative inhibitor, which are more complex than anticipated.
Collapse
Affiliation(s)
- Valérie Bégay
- Tumorigenesis and Cell Differentiation, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany. .,Molecular Physiology of Somatic Sensation, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany.
| | - Christian Baumeier
- Tumorigenesis and Cell Differentiation, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany.,Department of experimental Diabetology (DIAB), German Institute of Human Nutrition Potsdam-Rehbruecke (DifE), 14558, Nuthetal, Germany, German Center for Diabetes Research (DZD), München-Neuherberg, Germany
| | - Karin Zimmermann
- Tumorigenesis and Cell Differentiation, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany
| | - Arnd Heuser
- Pathophysiology Group, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany
| | - Achim Leutz
- Tumorigenesis and Cell Differentiation, Max Delbrueck Center for Molecular Medicine, Berlin, 13125, Berlin, Germany. .,Humboldt-University, Berlin, Institute of Biology, 10115, Berlin, Germany.
| |
Collapse
|
26
|
Wilck N, Markó L, Balogh A, Kräker K, Herse F, Bartolomaeus H, Szijártó IA, Gollasch M, Reichhart N, Strauss O, Heuser A, Brockschnieder D, Kretschmer A, Lesche R, Sohler F, Stasch JP, Sandner P, Luft FC, Müller DN, Dechend R, Haase N. Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. JCI Insight 2018; 3:96006. [PMID: 29467337 DOI: 10.1172/jci.insight.96006] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 01/11/2018] [Indexed: 12/17/2022] Open
Abstract
Heart failure with preserved ejection fraction (HFpEF) can arise from cardiac and vascular remodeling processes following long-lasting hypertension. Efficacy of common HF therapeutics is unsatisfactory in HFpEF. Evidence suggests that stimulators of the nitric oxide-sensitive soluble guanylyl cyclase (NOsGC) could be of use here. We aimed to characterize the complex cardiovascular effects of NOsGC stimulation using NO-independent stimulator BAY 41-8543 in a double-transgenic rat (dTGR) model of HFpEF. We show a drastically improved survival rate of treated dTGR. We observed less cardiac fibrosis, macrophage infiltration, and gap junction remodeling in treated dTGR. Microarray analysis revealed that treatment of dTGR corrected the dysregulateion of cardiac genes associated with fibrosis, inflammation, apoptosis, oxidative stress, and ion channel function toward an expression profile similar to healthy controls. Treatment reduced systemic blood pressure levels and improved endothelium-dependent vasorelaxation of resistance vessels. Further comprehensive in vivo phenotyping showed an improved diastolic cardiac function, improved hemodynamics, and less susceptibility to ventricular arrhythmias. Short-term BAY 41-8543 application in isolated untreated transgenic hearts with structural remodeling significantly reduced the occurrence of ventricular arrhythmias, suggesting a direct nongenomic role of NOsGC stimulation on excitation. Thus, NOsGC stimulation was highly effective in improving several HFpEF facets in this animal model, underscoring its potential value for patients.
Collapse
Affiliation(s)
- Nicola Wilck
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Lajos Markó
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | - András Balogh
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Kristin Kräker
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Florian Herse
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Hendrik Bartolomaeus
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany
| | - István A Szijártó
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Maik Gollasch
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Nadine Reichhart
- Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Olaf Strauss
- Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | | | | | - Ralf Lesche
- Bayer AG, Drug Discovery, Wuppertal & Berlin, Germany
| | | | | | - Peter Sandner
- Bayer AG, Drug Discovery, Wuppertal & Berlin, Germany
| | - Friedrich C Luft
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Dominik N Müller
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Ralf Dechend
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and BIH, Berlin, Germany.,HELIOS-Klinikum, Berlin, Germany
| | - Nadine Haase
- Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine and the Charité Medical Faculty, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Berlin, Germany.,Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| |
Collapse
|
27
|
Althof N, Goetzke CC, Kespohl M, Voss K, Heuser A, Pinkert S, Kaya Z, Klingel K, Beling A. The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol Med 2018; 10:200-218. [PMID: 29295868 PMCID: PMC5801517 DOI: 10.15252/emmm.201708089] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 11/28/2017] [Accepted: 12/01/2017] [Indexed: 01/04/2023] Open
Abstract
Severe heart pathology upon virus infection is closely associated with the immunological equipment of the host. Since there is no specific treatment available, current research focuses on identifying new drug targets to positively modulate predisposing immune factors. Utilizing a murine model with high susceptibility to coxsackievirus B3-induced myocarditis, this study describes ONX 0914-an immunoproteasome-specific inhibitor-as highly protective during severe heart disease. Represented by reduced heart infiltration of monocytes/macrophages and diminished organ damage, ONX 0914 treatment reversed fulminant pathology. Virus-induced immune response features like overwhelming pro-inflammatory cytokine and chemokine production as well as a progressive loss of lymphocytes all being reminiscent of a sepsis-like disease course were prevented by ONX 0914. Although the viral burden was only minimally affected in highly susceptible mice, resulting maintenance of immune homeostasis improved the cardiac output, and saved animals from severe illness as well as high mortality. Altogether, this could make ONX 0914 a potent drug for the treatment of severe virus-mediated inflammation of the heart and might rank immunoproteasome inhibitors among drugs for preventing pathogen-induced immunopathology.
Collapse
Affiliation(s)
- Nadine Althof
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Berlin, Germany
| | - Carl Christoph Goetzke
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
| | - Meike Kespohl
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Berlin, Germany
| | - Karolin Voss
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrueck-Center for Molecular Medicine Berlin, Berlin, Germany
| | - Sandra Pinkert
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
| | - Ziya Kaya
- Medizinische Klinik für Innere Medizin III: Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Heidelberg, Heidelberg, Germany
| | - Karin Klingel
- Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany
| | - Antje Beling
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Biochemistry, Berlin, Germany
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), partner side Berlin, Berlin, Germany
| |
Collapse
|
28
|
Rathjen T, Yan X, Kononenko NL, Ku MC, Song K, Ferrarese L, Tarallo V, Puchkov D, Kochlamazashvili G, Brachs S, Varela L, Szigeti-Buck K, Yi CX, Schriever SC, Tattikota SG, Carlo AS, Moroni M, Siemens J, Heuser A, van der Weyden L, Birkenfeld AL, Niendorf T, Poulet JFA, Horvath TL, Tschöp MH, Heinig M, Trajkovski M, Haucke V, Poy MN. Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule 1. Nat Neurosci 2017. [PMID: 28628102 PMCID: PMC5533218 DOI: 10.1038/nn.4590] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Susceptibility to obesity is linked to genes regulating neurotransmission, pancreatic β-cell function, and energy homeostasis. Genome-wide association studies identified an association between body mass index and two loci near Cell Adhesion Molecule1 (CADM1) and Cell Adhesion Molecule2 (CADM2), genes encoding membrane proteins mediating synaptic assembly. We show these respective risk variants associate with increased CADM1 and CADM2 expression in the hypothalamus of human subjects. Expression of both genes is elevated in obese mice and induction of Cadm1 in excitatory neurons facilitated weight gain while exacerbating energy expenditure. Loss of Cadm1 protected mice from obesity and tract-tracing analysis revealed Cadm1-positive innervation of POMC neurons via afferent projections originating from beyond the arcuate nucleus. Reducing Cadm1 expression in the hypothalamus and hippocampus promoted a negative energy balance and weight loss. These data identify roles for Cadm1-mediated neuronal input in weight regulation and provide insight into the central pathways contributing to human obesity.
Collapse
Affiliation(s)
- Thomas Rathjen
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Xin Yan
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Natalia L Kononenko
- Leibniz Institute for Molecular Pharmacology, Berlin, Germany.,CECAD Research Center, University of Cologne, Cologne, Germany.,Cluster of Excellence NeuroCure, Neuroscience Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Min-Chi Ku
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Kun Song
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Leiron Ferrarese
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Cluster of Excellence NeuroCure, Neuroscience Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Valentina Tarallo
- University of Geneva, Medical Faculty, Department of Cell Physiology and Metabolism, Centre Médical Universitaire (CMU), Geneva, Switzerland
| | - Dmytro Puchkov
- Leibniz Institute for Molecular Pharmacology, Berlin, Germany
| | | | - Sebastian Brachs
- Charité - Universitätsmedizin Berlin, Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Berlin, Germany
| | - Luis Varela
- Program in Integrative Cell Signaling and Neurobiology of Metabolism, Department of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Klara Szigeti-Buck
- Program in Integrative Cell Signaling and Neurobiology of Metabolism, Department of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Chun-Xia Yi
- Institute for Diabetes and Obesity, Helmholtz Centre for Health and Environment and Division of Metabolic Diseases, Technical University Munich, Munich, Germany
| | - Sonja C Schriever
- Institute for Diabetes and Obesity, Helmholtz Centre for Health and Environment and Division of Metabolic Diseases, Technical University Munich, Munich, Germany
| | | | | | - Mirko Moroni
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Jan Siemens
- Department of Pharmacology, University of Heidelberg, Heidelberg, Germany
| | - Arnd Heuser
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Louise van der Weyden
- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
| | - Andreas L Birkenfeld
- Section of Metabolic Vascular Medicine and Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine, TU Dresden, Medical Clinic III, University Clinic Dresden, Dresden, Germany.,Division of Diabetes and Nutritional Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
| | - Thoralf Niendorf
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - James F A Poulet
- Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Cluster of Excellence NeuroCure, Neuroscience Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Tamas L Horvath
- Program in Integrative Cell Signaling and Neurobiology of Metabolism, Department of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.,Department of Anatomy and Histology, University of Veterinary Sciences, Budapest, Hungary
| | - Matthias H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Centre for Health and Environment and Division of Metabolic Diseases, Technical University Munich, Munich, Germany
| | - Matthias Heinig
- Helmholtz Zentrum München, Institute of Computational Biology, Neuherberg, Germany
| | - Mirko Trajkovski
- University of Geneva, Medical Faculty, Department of Cell Physiology and Metabolism, Centre Médical Universitaire (CMU), Geneva, Switzerland
| | - Volker Haucke
- Leibniz Institute for Molecular Pharmacology, Berlin, Germany.,Cluster of Excellence NeuroCure, Neuroscience Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Matthew N Poy
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| |
Collapse
|
29
|
Heinecke K, Heuser A, Jux C, Thierfelder L, Drenckhahn J. Preserved Heart Function after Left Ventricular Pressure Overload in Adult Mice Subjected to Neonatal Cardiac Hypoplasia. Thorac Cardiovasc Surg 2017. [DOI: 10.1055/s-0037-1598860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- K. Heinecke
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - A. Heuser
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - C. Jux
- University Hospital Münster, Department of Pediatric Cardiology, Münster, Germany
| | - L. Thierfelder
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | | |
Collapse
|
30
|
Hytönen J, Leppänen O, Braesen JH, Schunck WH, Mueller D, Jung F, Mrowietz C, Jastroch M, von Bergwelt-Baildon M, Kappert K, Heuser A, Drenckhahn JD, Pieske B, Thierfelder L, Ylä-Herttuala S, Blaschke F. Activation of Peroxisome Proliferator–Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis. Arterioscler Thromb Vasc Biol 2016; 36:1534-48. [DOI: 10.1161/atvbaha.115.306962] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Accepted: 05/23/2016] [Indexed: 11/16/2022]
Abstract
Objective—
Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome proliferator–activated receptor-delta (PPARδ) exhibits actions that could favorably influence outcomes after drug-eluting coronary stents placement.
Approach and Results—
Here, we report that PPARδ ligand–coated stents strongly reduce the development of neointima and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using normal and PPARδ-depleted VSMCs, we show that the observed effects of PPARδ ligand GW0742 on VSMCs and thrombocytes are PPARδ receptor dependent. PPARδ ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide the increased energy demands required for growth factor–stimulated proliferation and migration.
Conclusions—
In contrast to commonly used drugs for stent coating, PPARδ ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPARδ activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.
Collapse
Affiliation(s)
- Jarkko Hytönen
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Olli Leppänen
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Jan Hinrich Braesen
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Wolf-Hagen Schunck
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Dominik Mueller
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Friedrich Jung
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Christoph Mrowietz
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Martin Jastroch
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Michael von Bergwelt-Baildon
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Kai Kappert
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Arnd Heuser
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Jörg-Detlef Drenckhahn
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Burkert Pieske
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Ludwig Thierfelder
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Seppo Ylä-Herttuala
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| | - Florian Blaschke
- From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular
| |
Collapse
|
31
|
Przybyl L, Haase N, Golic M, Rugor J, Solano ME, Arck PC, Gauster M, Huppertz B, Emontzpohl C, Stoppe C, Bernhagen J, Leng L, Bucala R, Schulz H, Heuser A, Weedon-Fekjær MS, Johnsen GM, Peetz D, Luft FC, Staff AC, Müller DN, Dechend R, Herse F. CD74-Downregulation of Placental Macrophage-Trophoblastic Interactions in Preeclampsia. Circ Res 2016; 119:55-68. [PMID: 27199465 DOI: 10.1161/circresaha.116.308304] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 05/19/2016] [Indexed: 01/28/2023]
Abstract
RATIONALE We hypothesized that cluster of differentiation 74 (CD74) downregulation on placental macrophages, leading to altered macrophage-trophoblast interaction, is involved in preeclampsia. OBJECTIVE Preeclamptic pregnancies feature hypertension, proteinuria, and placental anomalies. Feto-placental macrophages regulate villous trophoblast differentiation during placental development. Disturbance of this well-balanced regulation can lead to pathological pregnancies. METHODS AND RESULTS We performed whole-genome expression analysis of placental tissue. CD74 was one of the most downregulated genes in placentas from preeclamptic women. By reverse transcriptase-polymerase chain reaction, we confirmed this finding in early-onset (<34 gestational week, n=26) and late-onset (≥34 gestational week, n=24) samples from preeclamptic women, compared with healthy pregnant controls (n=28). CD74 protein levels were analyzed by Western blot and flow cytometry. We identified placental macrophages to express CD74 by immunofluorescence, flow cytometry, and RT-PCR. CD74-positive macrophages were significantly reduced in preeclamptic placentas compared with controls. CD74-silenced macrophages showed that the adhesion molecules ALCAM, ICAM4, and Syndecan-2, as well as macrophage adhesion to trophoblasts were diminished. Naive and activated macrophages lacking CD74 showed a shift toward a proinflammatory signature with an increased secretion of tumor necrosis factor-α, chemokine (C-C motif) ligand 5, and monocyte chemotactic protein-1, when cocultured with trophoblasts compared with control macrophages. Trophoblasts stimulated by these factors express more CYP2J2, sFlt1, TNFα, and IL-8. CD74-knockout mice showed disturbed placental morphology, reduced junctional zone, smaller placentas, and impaired spiral artery remodeling with fetal growth restriction. CONCLUSIONS CD74 downregulation in placental macrophages is present in preeclampsia. CD74 downregulation leads to altered macrophage activation toward a proinflammatory signature and a disturbed crosstalk with trophoblasts.
Collapse
Affiliation(s)
- Lukasz Przybyl
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Nadine Haase
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Michaela Golic
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Julianna Rugor
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Maria Emilia Solano
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Petra Clara Arck
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Martin Gauster
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Berthold Huppertz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Christoph Emontzpohl
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Christian Stoppe
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Jürgen Bernhagen
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Lin Leng
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Richard Bucala
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Herbert Schulz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Arnd Heuser
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - M Susanne Weedon-Fekjær
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Guro M Johnsen
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Dirk Peetz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Friedrich C Luft
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Anne Cathrine Staff
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Dominik N Müller
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Ralf Dechend
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Florian Herse
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.).
| |
Collapse
|
32
|
Lodka D, Pahuja A, Geers-Knörr C, Scheibe RJ, Nowak M, Hamati J, Köhncke C, Purfürst B, Kanashova T, Schmidt S, Glass DJ, Morano I, Heuser A, Kraft T, Bassel-Duby R, Olson EN, Dittmar G, Sommer T, Fielitz J. Muscle RING-finger 2 and 3 maintain striated-muscle structure and function. J Cachexia Sarcopenia Muscle 2016; 7:165-80. [PMID: 27493870 PMCID: PMC4863828 DOI: 10.1002/jcsm.12057] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 05/24/2015] [Accepted: 06/04/2015] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND The Muscle-specific RING-finger (MuRF) protein family of E3 ubiquitin ligases is important for maintenance of muscular structure and function. MuRF proteins mediate adaptation of striated muscles to stress. MuRF2 and MuRF3 bind to microtubules and are implicated in sarcomere formation with noticeable functional redundancy. However, if this redundancy is important for muscle function in vivo is unknown. Our objective was to investigate cooperative function of MuRF2 and MuRF3 in the skeletal muscle and the heart in vivo. METHODS MuRF2 and MuRF3 double knockout mice (DKO) were generated and phenotypically characterized. Skeletal muscle and the heart were investigated by morphological measurements, histological analyses, electron microscopy, immunoblotting, and real-time PCR. Isolated muscles were subjected to in vitro force measurements. Cardiac function was determined by echocardiography and working heart preparations. Function of cardiomyocytes was measured in vitro. Cell culture experiments and mass-spectrometry were used for mechanistic analyses. RESULTS DKO mice showed a protein aggregate myopathy in skeletal muscle. Maximal force development was reduced in DKO soleus and extensor digitorum longus. Additionally, a fibre type shift towards slow/type I fibres occurred in DKO soleus and extensor digitorum longus. MuRF2 and MuRF3-deficient hearts showed decreased systolic and diastolic function. Further analyses revealed an increased expression of the myosin heavy chain isoform beta/slow and disturbed calcium handling as potential causes for the phenotype in DKO hearts. CONCLUSIONS The redundant function of MuRF2 and MuRF3 is important for maintenance of skeletal muscle and cardiac structure and function in vivo.
Collapse
Affiliation(s)
- Dörte Lodka
- Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC) Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Campus Buch 13125 Berlin Germany
| | - Aanchal Pahuja
- Institute of Molecular and Cell Physiology Hannover Medical School 30625 Hannover Germany
| | - Cornelia Geers-Knörr
- Institute of Molecular and Cell Physiology Hannover Medical School 30625 Hannover Germany
| | - Renate J Scheibe
- Institute of Physiological Chemistry Hannover Medical School 30625 Hannover Germany
| | - Marcel Nowak
- Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC) Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Campus Buch 13125 Berlin Germany; Department of Intracellular Proteolysis Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Jida Hamati
- Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC) Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Campus Buch 13125 Berlin Germany
| | - Clemens Köhncke
- Department of Molecular Muscle Physiology Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Bettina Purfürst
- Department of Electron Microscopy Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Tamara Kanashova
- Department of Mass Spectrometry Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Sibylle Schmidt
- Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC) Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Campus Buch 13125 Berlin Germany
| | - David J Glass
- Novartis Institutes for Biomedical Research Cambridge Massachusetts 02139 USA
| | - Ingo Morano
- Department of Molecular Muscle Physiology Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Arnd Heuser
- Department of Cardiovascular Molecular Genetics Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Theresia Kraft
- Institute of Molecular and Cell Physiology Hannover Medical School 30625 Hannover Germany
| | - Rhonda Bassel-Duby
- Department of Molecular Biology University of Texas Southwestern Medical Center Dallas Texas 75390-9148 USA
| | - Eric N Olson
- Department of Molecular Biology University of Texas Southwestern Medical Center Dallas Texas 75390-9148 USA
| | - Gunnar Dittmar
- Department of Mass Spectrometry Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Thomas Sommer
- Department of Intracellular Proteolysis Max Delbrück Center for Molecular Medicine 13125 Berlin Germany
| | - Jens Fielitz
- Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC) Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Campus Buch 13125 Berlin Germany; Department of Cardiology Charité Universitätsmedizin Berlin, Campus Virchow 13353 Berlin Germany
| |
Collapse
|
33
|
Magarin M, Pohl T, Lill A, Schulz H, Blaschke F, Heuser A, Thierfelder L, Donath S, Drenckhahn JD. Embryonic cardiomyocytes can orchestrate various cell protective mechanisms to survive mitochondrial stress. J Mol Cell Cardiol 2016; 97:1-14. [PMID: 27106802 DOI: 10.1016/j.yjmcc.2016.04.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 04/15/2016] [Indexed: 02/06/2023]
Abstract
Whereas adult cardiomyocytes are highly susceptible to stress, cardiomyocytes in the prenatal heart appear to be rather resistant. To investigate how embryonic cardiomyocytes respond to metabolic stress in vivo, we utilized tissue mosaicism for mitochondrial dysfunction in 13.5dpc mouse hearts. The latter is based on inactivation of the X-linked gene encoding Holocytochrome c synthase (Hccs), which is essential for mitochondrial respiration. In heterozygous heart conditional Hccs knockout females (cHccs(+/-)) random X chromosomal inactivation results in a mosaic of healthy and HCCS deficient cells in the myocardium. Microarray RNA expression analyses identified genes involved in unfolded protein response (UPR) and programmed cell death as differentially expressed in cHccs(+/-) versus control embryonic hearts. Activation of the UPR is localized to HCCS deficient cardiomyocytes but does not involve ER stress pathways, suggesting that it is caused by defective mitochondria. Consistently, mitochondrial chaperones, such as HSP10 and HSP60, but not ER chaperones are induced in defective cells. Mitochondrial dysfunction can result in oxidative stress, but no evidence for excessive ROS (reactive oxygen species) production was observed in cHccs(+/-) hearts. Instead, the antioxidative proteins SOD2 and PRDX3 are induced, suggesting that ROS detoxification prevents oxidative damage in HCCS deficient cardiomyocytes. Mitochondrial dysfunction and unrestricted UPR can induce cell death, and we detected the initiation of upstream events of both intrinsic as well as extrinsic apoptosis in cHccs(+/-) hearts. Cell death is not executed, however, suggesting the activation of antiapoptotic mechanisms. Whereas most apoptosis inhibitors are either unchanged or downregulated in HCCS deficient cardiomyocytes, Bcl-2 and ARC (apoptosis repressor with caspase recruitment domain) are induced. Given that ARC can inhibit both apoptotic pathways as well as necrosis and attenuates UPR, we generated cHccs(+/-) embryos on an Arc knockout background (cHccs(+/-),Arc(-/-)). Surprisingly, the absence of ARC does not induce cell death in embryonic or postnatal HCCS deficient cardiomyocytes and adult cHccs(+/-),Arc(-/-) mice exhibit normal cardiac morphology and function. Taken together, our data demonstrate an impressive plasticity of embryonic cardiomyocytes to respond to metabolic stress, the loss of which might be involved in the high susceptibility of postnatal cardiomyocytes to cell death.
Collapse
Affiliation(s)
| | - Toni Pohl
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Anette Lill
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Herbert Schulz
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; Cologne Center for Genomics, University of Cologne, Cologne, Germany
| | - Florian Blaschke
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Kardiologie, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | | | - Stefan Donath
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Jörg-Detlef Drenckhahn
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; Department of Pediatric Cardiology, University Hospital Münster, Münster, Germany.
| |
Collapse
|
34
|
Haase N, Wilck N, Marko L, Balogh A, Heuser A, Brockschnieder D, Kretschmer A, Stasch JP, Müller N, Dechend R. The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure. BMC Pharmacol Toxicol 2015. [PMCID: PMC4565162 DOI: 10.1186/2050-6511-16-s1-a57] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
35
|
Drenckhahn JD, Strasen J, Heinecke K, Langner P, Yin KV, Skole F, Hennig M, Spallek B, Fischer R, Blaschke F, Heuser A, Cox TC, Black MJ, Thierfelder L. Impaired myocardial development resulting in neonatal cardiac hypoplasia alters postnatal growth and stress response in the heart. Cardiovasc Res 2015; 106:43-54. [PMID: 25661081 DOI: 10.1093/cvr/cvv028] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
AIMS Foetal growth has been proposed to influence cardiovascular health in adulthood, a process referred to as foetal programming. Indeed, intrauterine growth restriction in animal models alters heart size and cardiomyocyte number in the perinatal period, yet the consequences for the adult or challenged heart are largely unknown. The aim of this study was to elucidate postnatal myocardial growth pattern, left ventricular function, and stress response in the adult heart after neonatal cardiac hypoplasia in mice. METHODS AND RESULTS Utilizing a new mouse model of impaired cardiac development leading to fully functional but hypoplastic hearts at birth, we show that myocardial mass is normalized until early adulthood by accelerated physiological cardiomyocyte hypertrophy. Compensatory hypertrophy, however, cannot be maintained upon ageing, resulting in reduced organ size without maladaptive myocardial remodelling. Angiotensin II stress revealed aberrant cardiomyocyte growth kinetics in adult hearts after neonatal hypoplasia compared with normally developed controls, characterized by reversible overshooting hypertrophy. This exaggerated growth mainly depends on STAT3, whose inhibition during angiotensin II treatment reduces left ventricular mass in both groups but causes contractile dysfunction in developmentally impaired hearts only. Whereas JAK/STAT3 inhibition reduces cardiomyocyte cross-sectional area in the latter, it prevents fibrosis in control hearts, indicating fundamentally different mechanisms of action. CONCLUSION Impaired prenatal development leading to neonatal cardiac hypoplasia alters postnatal cardiac growth and stress response in vivo, thereby linking foetal programming to organ size control in the heart.
Collapse
Affiliation(s)
- Jörg-Detlef Drenckhahn
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Jette Strasen
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Kirsten Heinecke
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Patrick Langner
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Kom Voy Yin
- Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia
| | - Friederike Skole
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Maria Hennig
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Bastian Spallek
- Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Robert Fischer
- Experimental and Clinical Research Center, Charité Medical Faculty, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Florian Blaschke
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany Charité Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Kardiologie, Berlin, Germany
| | - Arnd Heuser
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| | - Timothy C Cox
- Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia Department of Pediatrics, University of Washington, Seattle, USA Center of Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, USA
| | - Mary Jane Black
- Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia
| | - Ludwig Thierfelder
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany
| |
Collapse
|
36
|
Markó L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Müller DN. Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling. Hypertension 2014; 64:1032-9. [PMID: 25185127 DOI: 10.1161/hypertensionaha.114.03900] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Angiotensin (Ang) II is a potent mediator of both hypertension and cardiac damage; however, the mechanisms by which this occur remain unclear. B-cell lymphoma/leukemia 10 (Bcl10) is a member of the CBM signalosome, which links Ang II and nuclear factor-κB signaling. We hypothesized that Bcl10 is pivotal in the pathogenesis of Ang II-induced cardiac damage. Ang II infusion in mice lacking Bcl10 resulted in reduced cardiac fibrosis, less cellular infiltration, and improved arrhythmogenic electric remodeling, despite a similar degree of hypertension or cardiac hypertrophy. Adoptive transfer of bone marrow (BM), whereby Bcl10 knockout or wildtype BM was transferred to their opposite genotype recipients, revealed the dual importance of Bcl10 within both cardiac and immune cells. Loss of Bcl10 in cardiac cells resulted in reduced expression of genes important for the adhesion and recruitment of immune cells. In vitro experiments demonstrated that adhesion of monocytes to Ang II-treated endothelial cells also required Bcl10. Additionally, Bcl10 deficiency in macrophages reduced their intrinsic migratory ability. To address the role of BM-derived fibroblasts in the formation of cardiac fibrosis, we explored whether Bcl10 is also important for the infiltration of BM-derived (myo)fibroblasts into the heart. The transfer of green fluorescent protein positive wildtype BM into Bcl10 knockout recipient mice revealed a reduced number of noncardiac (myo)fibroblasts compared with those wildtype recipients. Our results demonstrate the significant role of Bcl10 in multiple cell types important for the generation of Ang II-induced cardiac damage and electric remodeling and may provide a new avenue for therapeutic intervention.
Collapse
Affiliation(s)
- Lajos Markó
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Norbert Henke
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Joon-Keun Park
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Bastian Spallek
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Fatimunnisa Qadri
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - András Balogh
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Ingrid J Apel
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Katherine I Oravecz-Wilson
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Mira Choi
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Lukasz Przybyl
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Katrina J Binger
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Nadine Haase
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Nicola Wilck
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Arnd Heuser
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Verena Fokuhl
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Jürgen Ruland
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Peter C Lucas
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Linda M McAllister-Lucas
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Friedrich C Luft
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Ralf Dechend
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.)
| | - Dominik N Müller
- From the Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., B.S., F.Q., A.B., M.C., L.P., K.J.B., N.H., N.W., V.F., F.C.L., R.D., D.N.M.); Department of Internal Medicine/Cardiology, Helios Clinic Damp, Damp, Germany (N.H.); Clinic for Nephrology and Hypertension, Hannover Medical School, Hannover, Germany (J.K.P.); Department of Pathology, University of Michigan Medical School, Ann Arbor, MI (I.J.A., K.I.O.W.); Max-Delbrück Center for Molecular Medicine, Berlin, Germany (L.M., A.B., K.J.B., A.H., F.C.L., D.N.M.); Institute for Clinical Chemistry and Biochemistry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany (J.R.); Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.C.L.); Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA (L.M.M.-L.); and Department of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Berlin, Germany (R.D.).
| |
Collapse
|
37
|
Suess E, Torres M, Bohrmann G, Collier R, Rickert D, Goldfinger C, Linke P, Heuser A, Sahling H, Heeschen K, Jung C, Nakamura K, Greinert J, Pfannkuche O, Trehu A, Klinkhammer G, Whiticar M, Eisenhauer A, Teichert B, Elver M. Sea Floor Methane Hydrates at Hydrate Ridge, Cascadia Margin. ACTA ACUST UNITED AC 2013. [DOI: 10.1029/gm124p0087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2023]
|
38
|
Vollert S, Kaessner N, Heuser A, Hanauer G, Dieckmann A, Knaack D, Kley HP, Beume R, Weiss-Haljiti C. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia 2012; 55:2779-2788. [PMID: 22790061 DOI: 10.1007/s00125-012-2632-z] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2012] [Accepted: 05/31/2012] [Indexed: 02/06/2023]
Abstract
AIMS/HYPOTHESIS The cAMP-degrading phosphodiesterase 4 (PDE4) enzyme has recently been implicated in the regulation of glucagon-like peptide-1 (GLP-1), an incretin hormone with glucose-lowering properties. We investigated whether the PDE4 inhibitor roflumilast elevates GLP-1 levels in diabetic db/db mice and whether this elevation is accompanied by glucose-lowering effects. METHODS Plasma GLP-1 was determined in db/db mice after single oral administration of roflumilast or its active metabolite roflumilast-N-oxide. Diabetes-relevant variables including HbA(1c), blood glucose, serum insulin, body weight, food and water intake, and pancreas morphology were determined in db/db mice treated daily for 28 days with roflumilast or roflumilast-N-oxide. Pharmacokinetic/pharmacodynamic analysis clarified the contribution of roflumilast vs its metabolite. In addition, the effect of roflumilast-N-oxide on insulin release was investigated in primary mouse islets. RESULTS Single treatment of db/db mice with 10 mg/kg roflumilast or roflumilast-N-oxide enhanced plasma GLP-1 2.5- and fourfold, respectively. Chronic treatment of db/db mice with roflumilast or roflumilast-N-oxide at 3 mg/kg showed prevention of disease progression. Roflumilast-N-oxide abolished the increase in blood glucose, reduced the increment in HbA(1c) by 50% and doubled fasted serum insulin compared with vehicle, concomitant with preservation of pancreatic islet morphology. Furthermore, roflumilast-N-oxide amplified forskolin-induced insulin release in primary islets. Roflumilast-N-oxide showed stronger glucose-lowering effects than its parent compound, consistent with its greater effect on GLP-1 secretion and explainable by pharmacokinetic/pharmacodynamic modelling. CONCLUSIONS/INTERPRETATION Our results suggest that roflumilast and roflumilast-N-oxide delay the progression of diabetes in db/db mice through protection of pancreatic islet physiology potentially involving GLP-1 and insulin activities.
Collapse
Affiliation(s)
- S Vollert
- Nycomed: a Takeda company, Nycomed GmbH, Institute of Pharmacology and Preclinical Drug Safety, Department RDP/LP, Haidkrugsweg 1, 22885, Barsbüttel, Germany.
| | | | - A Heuser
- Nycomed: a Takeda company, Nycomed GmbH, Institute of Pharmacology and Preclinical Drug Safety, Department RDP/LP, Haidkrugsweg 1, 22885, Barsbüttel, Germany
| | | | | | - D Knaack
- Actelion Pharmaceuticals, Allschwil, Switzerland
| | | | | | | |
Collapse
|
39
|
An J, Harms C, Lättig-Tünnemann G, Sellge G, Mandić AD, Malato Y, Heuser A, Endres M, Trautwein C, Donath S. TAT-apoptosis repressor with caspase recruitment domain protein transduction rescues mice from fulminant liver failure. Hepatology 2012; 56:715-26. [PMID: 22392694 DOI: 10.1002/hep.25697] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Accepted: 02/24/2012] [Indexed: 12/18/2022]
Abstract
UNLABELLED Acute liver failure (ALF) is associated with massive hepatocyte cell death and high mortality rates. Therapeutic approaches targeting hepatocyte injury in ALF are hampered by the activation of distinct stimulus-dependent pathways, mechanism of cell death, and a limited therapeutic window. The apoptosis repressor with caspase recruitment domain (ARC) is a recently discovered death repressor that inhibits both death receptor and mitochondrial apoptotic signaling. Here, we investigated the in vivo effects of ARC fused with the transduction domain of human immunodeficiency virus 1 (HIV-1) (TAT-ARC) on Fas- and tumor necrosis factor (TNF)-mediated murine models of fulminant liver failure. Treatment with TAT-ARC protein completely abrogated otherwise lethal liver failure induced by Fas-agonistic antibody (Jo2), concanavalin A (ConA), or D-galactosamine/lipopolysaccharide (GalN/LPS) administration. Importantly, survival of mice was even preserved when TAT-ARC therapy was initiated in a delayed manner after stimulation with Jo2, ConA, or GalN/LPS. ARC blocked hepatocyte apoptosis by directly interacting with members of the death-inducing signaling complex. TNF-mediated liver damage was inhibited by two independent mechanisms: inhibition of jun kinase (JNK)-mediated TNF-α expression and prevention of hepatocyte apoptosis by inhibition of both death receptor and mitochondrial death signaling. We identified JNK as a novel target of ARC. ARC's caspase recruitment domain (CARD) directly interacts with JNK1 and JNK2, which correlates with decreased JNK activation and JNK-dependent TNF-α production. CONCLUSION This work suggests that ARC confers hepatoprotection upstream and at the hepatocyte level. The efficacy of TAT-ARC protein transduction in multiple murine models of ALF demonstrates its therapeutic potential for reversing liver failure.
Collapse
Affiliation(s)
- Junfeng An
- Max-Delbrück Center for Molecular Medicine, Berlin, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Wenzel K, Wallukat G, Qadri F, Hubner N, Schulz H, Hummel O, Herse F, Heuser A, Fischer R, Heidecke H, Luft FC, Muller DN, Dietz R, Dechend R. Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. PLoS One 2010; 5:e9409. [PMID: 20195525 PMCID: PMC2827566 DOI: 10.1371/journal.pone.0009409] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2009] [Accepted: 01/16/2010] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Agonistic autoantibodies to the alpha(1)-adrenergic receptor occur in nearly half of patients with refractory hypertension; however, their relevance is uncertain. METHODS/PRINCIPAL FINDINGS We immunized Lewis rats with the second extracellular-loop peptides of the human alpha(1A)-adrenergic receptor and maintained them for one year. Alpha(1A)-adrenergic antibodies (alpha(1A)-AR-AB) were monitored with a neonatal cardiomyocyte contraction assay by ELISA, and by ERK1/2 phosphorylation in human alpha(1A)-adrenergic receptor transfected Chinese hamster ovary cells. The rats were followed with radiotelemetric blood pressure measurements and echocardiography. At 12 months, the left ventricles of immunized rats had greater wall thickness than control rats. The fractional shortening and dp/dt(max) demonstrated preserved systolic function. A decreased E/A ratio in immunized rats indicated a diastolic dysfunction. Invasive hemodynamics revealed increased left ventricular end-diastolic pressures and decreased dp/dt(min). Mean diameter of cardiomyocytes showed hypertrophy in immunized rats. Long-term blood pressure values and heart rates were not different. Genes encoding sarcomeric proteins, collagens, extracellular matrix proteins, calcium regulating proteins, and proteins of energy metabolism in immunized rat hearts were upregulated, compared to controls. Furthermore, fibrosis was present in immunized hearts, but not in control hearts. A subset of immunized and control rats was infused with angiotensin (Ang) II. The stressor raised blood pressure to a greater degree and led to more cardiac fibrosis in immunized, than in control rats. CONCLUSIONS/SIGNIFICANCE We show that alpha(1A)-AR-AB cause diastolic dysfunction independent of hypertension, and can increase the sensitivity to Ang II. We suggest that alpha(1A)-AR-AB could contribute to cardiovascular endorgan damage.
Collapse
|
41
|
Park JK, Theuer S, Kirsch T, Lindschau C, Klinge U, Heuser A, Plehm R, Todiras M, Carmeliet P, Haller H, Luft FC, Muller DN, Fiebeler A. Growth arrest specific protein 6 participates in DOCA-induced target-organ damage. Hypertension 2009; 54:359-64. [PMID: 19564549 DOI: 10.1161/hypertensionaha.109.129460] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Growth arrest-specific protein 6 (Gas 6) is involved in inflammatory kidney diseases, vascular remodeling, cell adhesion, and thrombus formation. We explored a role for Gas 6 in aldosterone-induced target organ damage. We observed that Gas 6 was upregulated in rats with high aldosterone levels. Mineralocorticoid receptor blockade prevented target organ damage and decreased the elevated Gas 6 expression. Vascular smooth muscle cells given aldosterone increased their Gas 6 expression in vitro. To test the pathophysiological relevance, we investigated the effects of deoxycorticosterone acetate (DOCA) on Gas 6 gene-deleted ((-/-)) mice. After 6 weeks DOCA, Gas 6(-/-) mice developed similar telemetric blood pressure elevations compared to wild-type mice but were protected from cardiac hypertrophy. Cardiac expression of interleukin 6 and collagen IV was blunted in Gas 6(-/-) mice, indicating reduced inflammation and fibrosis. Gas 6(-/-) mice also had an improved renal function with reduced albuminuria, compared to wild-type mice. Renal fibrosis and fibronectin deposition in the kidney were also reduced. Gas 6 deficiency reduces the detrimental effects of aldosterone on cardiac and renal remodeling independent of blood pressure reduction. Gas 6 appears to play a role in mineralocorticoid receptor-mediated target organ damage. Furthermore, because warfarin interferes with Gas 6 protein expression, the findings could be of clinical relevance for anticoagulant choices.
Collapse
|
42
|
Gramlich M, Michely B, Krohne C, Heuser A, Erdmann B, Klaassen S, Hudson B, Magarin M, Kirchner F, Todiras M, Granzier H, Labeit S, Thierfelder L, Gerull B. Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. J Mol Cell Cardiol 2009; 47:352-8. [PMID: 19406126 DOI: 10.1016/j.yjmcc.2009.04.014] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2009] [Revised: 04/15/2009] [Accepted: 04/15/2009] [Indexed: 10/20/2022]
Abstract
Mutations in a variety of myofibrillar genes cause dilated cardiomyopathy (DCM) in humans, usually with dominant inheritance and incomplete penetrance. Here, we sought to clarify the functional effects of the previously identified DCM-causing TTN 2-bp insertion mutation (c.43628insAT) and generated a titin knock-in mouse model mimicking the c.43628insAT allele. Mutant embryos homozygous for the Ttn knock-in mutation developed defects in sarcomere formation and consequently died before E9.5. Heterozygous mice were viable and demonstrated normal cardiac morphology, function and muscle mechanics. mRNA and protein expression studies on heterozygous hearts demonstrated elevated wild-type titin mRNA under resting conditions, suggesting that up-regulation of the wild-type titin allele compensates for the unstable mutated titin under these conditions. When chronically exposed to angiotensin II or isoproterenol, heterozygous mice developed marked left ventricular dilatation (p<0.05) with impaired fractional shortening (p<0.001) and diffuse myocardial fibrosis (11.95+/-2.8% vs. 3.7+/-1.1%). Thus, this model mimics typical features of human dilated cardiomyopathy and may further our understanding of how titin mutations perturb cardiac function and remodel the heart.
Collapse
Affiliation(s)
- Michael Gramlich
- Max-Delbrueck Center for Molecular Medicine, Robert-Roessle-Str. 10, 13125 Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, Gapelyuk A, Safak E, Zacharzowsky U, Heuser A, Schirdewan A, Luft F, Schunck WH, Muller D. ω-3 polyunsaturated fatty acids and direct renin inhibition—2 ways to improve electrical remodeling. J Electrocardiol 2008. [DOI: 10.1016/j.jelectrocard.2008.08.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
da Costa-Goncalves AC, Tank J, Plehm R, Diedrich A, Todiras M, Gollasch M, Heuser A, Wellner M, Bader M, Jordan J, Luft FC, Gross V. Role of the Multidomain Protein Spinophilin in Blood Pressure and Cardiac Function Regulation. Hypertension 2008; 52:702-7. [DOI: 10.1161/hypertensionaha.108.114355] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Spinophilin controls intensity/duration of G protein-coupled receptor signaling and thereby influences synaptic activity. We hypothesize that spinophilin affects blood pressure through central mechanisms. We measured blood pressure and heart rate in SPL-deficient (SPL
−/−
), heterozygous SPL-deficient (SPL
+/−
), and wild-type (SPL
+/+
) mice by telemetry combined with fast Fourier transformation. We also assessed peripheral vascular reactivity and performed echocardiography. SPL
−/−
had higher mean arterial pressure than SPL
+/−
and SPL
+/+
(121±2, 112±1, and 113±1 mm Hg). Heart rate was inversely related to spinophilin expression (SPL
−/−
565±0.4, SPL
+/−
541±5, SPL
+/+
525±8 bpm). The blood pressure response to prazosin, trimethapane, and the heart rate response to metoprolol were stronger in SPL
−/−
than SPL
+/+
mice, whereas heart rate response to atropine was attenuated in SPL
−/−
. Mesenteric artery vasoreactivity after angiotensin II, phenylephrine, and the thromboxane mimetic (U46619) as well as change in heart rate, stroke volume, and cardiac output after dobutamine were similar in SPL
−/−
and SPL
+/+
. Baroreflex sensitivity was attenuated in SPL
−/−
compared with SPL
+/−
and SPL
+/+
, which was confirmed by pharmacological testing. Heart rate variability parameters were attenuated in SPL
−/−
mice. We suggest that an increase in central sympathetic outflow participates in blood pressure and heart rate increases in SPL
−/−
mice. The elevated blood pressure in SPL
−/−
mice was associated with attenuated baroreflex sensitivity and decreased parasympathetic activity. Our study is the first to show a role for the spinophilin gene in blood pressure regulation.
Collapse
Affiliation(s)
- Andrey C. da Costa-Goncalves
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Jens Tank
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Ralph Plehm
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Andre Diedrich
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Mihail Todiras
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Maik Gollasch
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Arnd Heuser
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Maren Wellner
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Michael Bader
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Jens Jordan
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Friedrich C. Luft
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| | - Volkmar Gross
- From the Max Delbrück Center for Molecular Medicine (A.C.d.C.G., R.P., M.T., A.H., M.W., M.B., F.C.L., V.G.), Berlin, Germany; the Institute of Clinical Pharmacology (J.T., J.J.), Hannover Medical School, Hannover, Germany; the Department of Medicine (A.D.), Division of Clinical Pharmacology, Autonomic Dysfunction Service, Vanderbilt University School of Medicine, Nashville, Tenn; the Charite University Medicine (M.G.), Section Nephrology/Intensive Care; and the Medical Faculty of the Charite (F.C
| |
Collapse
|
45
|
Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, Schuler P, Greutmann M, Hürlimann D, Yegitbasi M, Pons L, Gramlich M, Drenckhahn JD, Heuser A, Berger F, Jenni R, Thierfelder L. Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation 2008; 117:2893-901. [PMID: 18506004 DOI: 10.1161/circulationaha.107.746164] [Citation(s) in RCA: 305] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND Left ventricular noncompaction constitutes a primary cardiomyopathy characterized by a severely thickened, 2-layered myocardium, numerous prominent trabeculations, and deep intertrabecular recesses. The genetic basis of this cardiomyopathy is still largely unresolved. We speculated that mutations in sarcomere protein genes known to cause hypertrophic cardiomyopathy and dilated cardiomyopathy may be associated with left ventricular noncompaction. METHODS AND RESULTS Mutational analysis in a cohort of 63 unrelated adult probands with left ventricular noncompaction and no other congenital heart anomalies was performed by denaturing high-performance liquid chromatography analysis and direct DNA sequencing of 6 genes encoding sarcomere proteins. Heterozygous mutations were identified in 11 of 63 samples in genes encoding beta-myosin heavy chain (MYH7), alpha-cardiac actin (ACTC), and cardiac troponin T (TNNT2). Nine distinct mutations, 7 of them in MYH7, 1 in ACTC, and 1 in TNNT2, were found. Clinical evaluations demonstrated familial disease in 6 of 11 probands with sarcomere gene mutations. MYH7 mutations segregated with the disease in 4 autosomal dominant LVNC kindreds. Six of the MYH7 mutations were novel, and 1 encodes a splice-site mutation, a relatively unique finding for MYH7 mutations. Modified residues in beta-myosin heavy chain were located mainly within the ATP binding site. CONCLUSIONS We conclude that left ventricular noncompaction is within the diverse spectrum of cardiac morphologies triggered by sarcomere protein gene defects. Our findings support the hypothesis that there is a shared molecular etiology of different cardiomyopathic phenotypes.
Collapse
Affiliation(s)
- Sabine Klaassen
- Max Delbrück Center for Molecular Medicine, Robert Roessle Strasse 10, 13092 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Hubner N, Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Goesele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz H, Patone G, Saar K, Vingron M, Weldon SM, Hammock BD, Rohde K, Dietz R, Cook SA, Schunck W, Luft FC. Soluble epoxide hydrolase (Ephx2) is a susceptibility gene for heart failure in a rat model of human disease 3044. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.479.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Jan Monti
- Department of Clinical and Molecular CardiologyFranz‐Volhard ClinicHelios Clinics GmbHCharité Universitaetsmedizin BerlinBerlinGermany
| | | | | | | | | | | | - Arnd Heuser
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | | | | | - Alexander Schirdewan
- Department of Clinical and Molecular CardiologyFranz‐Volhard ClinicHelios Clinics GmbHCharité Universitaetsmedizin BerlinBerlinGermany
| | - Volkmar Gross
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | - Oliver Hummel
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | - Henrike Maatz
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | | | - Kathrin Saar
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | - Martin Vingron
- Department of BioinformaticsMax‐Planck‐Institute for Molecular GeneticsBerlinGermany
| | | | - Bruce D. Hammock
- Departments of Entomology and Nutrition and Cancer Research CenterUC DavisSacramentoCA
| | - Klaus Rohde
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | - Rainer Dietz
- Max‐Delbruck‐Center for Molecular MedicineBerlinGermany
| | - Stuart A. Cook
- MRC Clinical Sciences Centre Faculty of MedicineImperial CollegeLondonUnited Kingdom
| | | | | |
Collapse
|
47
|
Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F, Park JK, Gapelyuk A, Schwarz I, Zacharzowsky UB, Plehm R, Safak E, Heuser A, Schirdewan A, Luft FC, Schunck WH, Muller DN. Dietary n-3 Polyunsaturated Fatty Acids and Direct Renin Inhibition Improve Electrical Remodeling in a Model of High Human Renin Hypertension. Hypertension 2008; 51:540-6. [DOI: 10.1161/hypertensionaha.107.103143] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We compared the effect n-3 polyunsaturated fatty acids (PUFAs) with direct renin inhibition on electrophysiological remodeling in angiotensin II–induced cardiac injury. We treated double-transgenic rats expressing the human renin and angiotensinogen genes (dTGRs) from week 4 to 7 with n-3 PUFA ethyl-esters (Omacor; 25-g/kg diet) or a direct renin inhibitor (aliskiren; 3 mg/kg per day). Sprague-Dawley rats were controls. We performed electrocardiographic, magnetocardiographic, and programmed electrical stimulation. Dietary n-3 PUFAs increased the cardiac content of eicosapentaenoic and docosahexaenoic acid. At week 7, mortality in dTGRs was 31%, whereas none of the n-3 PUFA- or aliskiren-treated dTGRs died. Systolic blood pressure was modestly reduced in n-3 PUFA-treated (180±3 mm Hg) compared with dTGRs (208±5 mm Hg). Aliskiren-treated dTGRs and Sprague-Dawley rats were normotensive (110±3 and 119±6 mm Hg, respectively). Both n-3 PUFA–treated and untreated dTGRs showed cardiac hypertrophy and increased atrial natriuretic peptide levels. Prolonged QRS and QT
c
intervals and increased T-wave dispersion in dTGRs were reduced by n-3 PUFAs or aliskiren. Both treatments reduced arrhythmia induction from 75% in dTGRs to 17% versus 0% in Sprague-Dawley rats. Macrophage infiltration and fibrosis were reduced by n-3 PUFAs and aliskiren. Connexin 43, a mediator of intermyocyte conduction, was redistributed to the lateral cell membranes in dTGRs. n-3 PUFAs and aliskiren restored normal localization to the intercalated disks. Thus, n-3 PUFAs and aliskiren improved electrical remodeling, arrhythmia induction, and connexin 43 expression, despite a 70-mm Hg difference in blood pressure and the development of cardiac hypertrophy.
Collapse
Affiliation(s)
- Robert Fischer
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Ralf Dechend
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Fatimunnisa Qadri
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Marija Markovic
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Sandra Feldt
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Florian Herse
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Joon-Keun Park
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Andrej Gapelyuk
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Ines Schwarz
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Udo B. Zacharzowsky
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Ralph Plehm
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Erdal Safak
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Arnd Heuser
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Alexander Schirdewan
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Friedrich C. Luft
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Wolf-Hagen Schunck
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| | - Dominik N. Muller
- From the Medical Faculty of the Charité (R.F., R.D., S.F., F.H., A.G., I.S., U.B.Z., E.S., A.S., F.C.L., D.N.M.), Experimental and Clinical Research Center, Franz Volhard Clinic and HELIOS Klinikum Berlin-Buch, Berlin, Germany; Max-Delbrueck-Center for Molecular Medicine (F.Q., M.M., R.P., A.H., F.C.L., W-H.S., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (J-K.P.), Hannover, Germany
| |
Collapse
|
48
|
Heuser A, Plovie ER, Ellinor PT, Grossmann KS, Shin JT, Wichter T, Basson CT, Lerman BB, Sasse-Klaassen S, Thierfelder L, MacRae CA, Gerull B. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006; 79:1081-8. [PMID: 17186466 PMCID: PMC1698714 DOI: 10.1086/509044] [Citation(s) in RCA: 177] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2006] [Accepted: 09/06/2006] [Indexed: 12/16/2022] Open
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically heterogeneous heart-muscle disorder characterized by progressive fibrofatty replacement of right ventricular myocardium and an increased risk of sudden cardiac death. Mutations in desmosomal proteins that cause ARVC have been previously described; therefore, we investigated 88 unrelated patients with the disorder for mutations in human desmosomal cadherin desmocollin-2 (DSC2). We identified a heterozygous splice-acceptor-site mutation in intron 5 (c.631-2A-->G) of the DSC2 gene, which led to the use of a cryptic splice-acceptor site and the creation of a downstream premature termination codon. Quantitative analysis of cardiac DSC2 expression in patient specimens revealed a marked reduction in the abundance of the mutant transcript. Morpholino knockdown in zebrafish embryos revealed a requirement for dsc2 in the establishment of the normal myocardial structure and function, with reduced desmosomal plaque area, loss of the desmosome extracellular electron-dense midlines, and associated myocardial contractility defects. These data identify DSC2 mutations as a cause of ARVC in humans and demonstrate that physiologic levels of DSC2 are crucial for normal cardiac desmosome formation, early cardiac morphogenesis, and cardiac function.
Collapse
Affiliation(s)
- Arnd Heuser
- Max-Delbrueck Center for Molecular Medicine, Franz-Volhard Clinic, HELIOS Clinics GmbH, Charité, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ellinor PT, Sasse-Klaassen S, Probst S, Gerull B, Shin JT, Toeppel A, Heuser A, Michely B, Yoerger DM, Song BS, Pilz B, Krings G, Coplin B, Lange PE, Dec GW, Hennies HC, Thierfelder L, MacRae CA. A novel locus for dilated cardiomyopathy, diffuse myocardial fibrosis, and sudden death on chromosome 10q25-26. J Am Coll Cardiol 2006; 48:106-11. [PMID: 16814656 DOI: 10.1016/j.jacc.2006.01.079] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2005] [Revised: 12/30/2005] [Accepted: 01/09/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVES We sought to identify the genetic locus for an inherited form of dilated cardiomyopathy (DCM) that is characterized by diffuse myocardial fibrosis and sudden death. BACKGROUND Genetic studies have mapped multiple loci for DCM, which is a major cause of nonischemic heart failure; however, the genes responsible for the majority of cases have yet to be identified. METHODS Sixty-six family members were evaluated by 12-lead electrocardiogram (ECG), echocardiogram, and laboratory studies. Individuals with echocardiographically documented DCM were defined as affected. Subjects were considered unaffected if they were older than 20 years of age, had a normal ECG and echocardiogram, no personal history of heart failure, and had no affected offspring. Genotyping was performed using polymorphic markers. RESULTS Genome-wide linkage analysis identified a novel locus for this inherited phenotype on chromosome 10q25.3-q26.13. Peak two-point logarithm of the odds scores >3.0 were obtained independently with each family using the markers D10S1773 and D10S1483, respectively. Haplotype analyses defined a critical interval of 14.0 centiMorgans between D10S1237 and D10S1723, corresponding to a physical distance of 9.5 megabases. Multipoint linkage analyses confirmed this interval and generated a peak logarithm of the odds score of 8.2 indicating odds of >100,000,000:1 in favor of this interval as the location of the gene defect responsible for DCM in these families. CONCLUSIONS We have mapped a novel locus for cardiomyopathy, diffuse myocardial fibrosis, and sudden death to chromosome 10q25-q26. The identification of the causative gene in this interval will be an important step in understanding the fundamental mechanisms of heart failure and sudden death.
Collapse
Affiliation(s)
- Patrick T Ellinor
- Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Gerull B, Atherton J, Geupel A, Sasse-Klaassen S, Heuser A, Frenneaux M, McNabb M, Granzier H, Labeit S, Thierfelder L. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med (Berl) 2006; 84:478-83. [PMID: 16733766 DOI: 10.1007/s00109-006-0060-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2005] [Accepted: 03/27/2006] [Indexed: 10/24/2022]
Abstract
Dilated cardiomyopathy (DCM) is an etiologically heterogeneous cardiac disease characterized by left ventricular dilation and systolic dysfunction. Approximately 25-30% of DCM patients show a family history of mainly autosomal dominant inheritance. We and others have previously demonstrated that mutations in the giant muscle filament titin (TTN) can cause DCM. However, the prevalence of titin mutations in familial DCM is unknown. In this paper, we report a novel heterozygous 1-bp deletion mutation (c.62890delG) in TTN that cosegregates with DCM in a large Australian pedigree (A3). The TTN deletion mutation c.62890delG causes a frameshift, thereby generating a truncated A-band titin due to a premature stop codon (p.E20963KfsX10) and the addition of ten novel amino acid residues. The clinical phenotype of DCM in kindred A3 demonstrates incomplete penetrance and variable expressivity. Finally, protein analysis of a skeletal muscle biopsy sample from an affected member did not reveal the predicted truncated titin isoform although the aberrant mRNA was present, suggesting posttranslational modification and degradation of the truncated protein. The identification of a novel disease-causing mutation in the giant titin gene in a third large family with DCM indicates that mutations in titin may account for a significant portion of the genetic etiology in familial DCM.
Collapse
Affiliation(s)
- Brenda Gerull
- Max-Delbrueck Center for Molecular Medicine, Robert-Roessle-Str. 10, 13092, Berlin-Buch, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|